

(Table 1). On phylogenetic analysis, strain KDH651 was found to be clustered with strain CK20043, and several human G9 and G12 strains (Fig. 3k).

#### 4. Discussion

In the present study, we analyzed the whole genomes of three African G12 strains that have emerged in Kenya (RVA/Human-tc/KEN/KDH633/2010/G12P[6], RVA/Human-tc/KEN/KDH651/2010/G12P[8], and RVA/Human-tc/KEN/KDH684/2010/G12P[6]) identified in three stool samples from children with gastroenteritis. All the three Kenyan G12 strains were found to have a Wa-like backbone: G12-P[6]-I1-R1-C1-M1-A1-N1-T1-E1-H1 (strains KDH633 and KDH684) and G12-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1 (strain KDH651). Whole genomic analyses of currently circulating G12 strains from different parts of the world have revealed the predominant possession of a Wa-like genetic backbone by them (Rahman et al., 2007). Because a Wa-like genotype backbone is believed to be one of the stable genetic constellations of human RVAs, the Wa-like backbone might have conferred an evolutionary advantage on G12 strains, making it possible for them to emerge globally in a surprising short time (Ghosh and Kobayashi, 2011; Matthijssens et al., 2008; Matthijssens and Van Ranst, 2012). Phylogenetic analysis revealed that most genes of the three strains examined in this study were genetically related to globally circulating G1, G9, and G12 strains. Furthermore, strains KDH633 and KDH684 were very closely related with each other in all the 11 genes, indicating the derivation of the two strains from a common origin. On the other hand, strain KDH651 consistently formed distinct clusters for 10 of the 11 gene segments (VP1-2, VP4, VP6-7, and NSP1-5), indicating its distinct origin from that of strains KDH633 and KDH684. Thus, the G12 strains that have emerged in Kenya appeared to have originated from not a single, but at least two distinct ancestral G12 strains.

Notably, the NSP4 genes of strains KDH633 and KDH684 appeared to be of porcine origin. However, the exact origin of the NSP4 genes of these strains could not be ascertained due to a lack of a sufficient number of representative strains as references. Therefore, we could not determine if the suspected ancestral G12 strain of strains KDH633 and KDH684 had the porcine-like NSP4 gene in its genome before it was introduced into Kenya. It should be noted that while our manuscript was under review, nucleotide sequences of three human strains from three different countries in Africa (RVA/Human-wt/TGO/MRC-DPRU1689/2008/G12P[6], RVA/Human-wt/ZMB/MRC-DPRU3507/2009/G12P[6], and RVA/Human-wt/UGA/MRC-DPRU3713/2010/G12P[6]) were deposited in the DDBJ and EMBL/GenBank data libraries. The NSP4 genes of these strains showed 99.4–99.7% nucleotide sequence identities with the cognate genes of strains KDH633 and KDH684 (Table 1). Furthermore, on phylogenetic analysis, these strains were found to be closely related with strains KDH633 and KDH684 within the porcine-like E1 subcluster (Fig. 3j). Thus, these African G12 strains isolated in different locations in the continent (Kenya, Togo, Uganda, and Zambia) might have derived from a common ancestral strain possessing the porcine-like NSP4 gene. In any case, strains KDH633 and KDH684 were assumed to be the result of reassortment between human and porcine strains. To our knowledge, this is the first description on full genome-based characterization of the G12 strains that have emerged in Kenya.

The increasing detection of G12 strains in Africa implies the ongoing expansion of G12 strains in the African continent. Because it has not been examined whether or not two available RVA vaccines (Rotarix (GlaxoSmithKline) and RotaTeq (Merck)) are effective for prevention against unusual strains, such as G12P[6] strains that share no G and P genotype specificities with strains

in these vaccines, continuing RVA surveillance of the G12 genotype is required. Simultaneous monitoring of RVA strains in humans and animals is also essential for a better understanding of RVA ecology. Furthermore, whole genome-based studies are essential to understand the evolutionary dynamics of emerging G12 strains in Africa.

#### Acknowledgements

We thank Director of Kenya Medical Research Institute for his collaborative support. This study was supported in part by a Cooperative Research Grant from NEKKEN, and Health and Labor Sciences Research Grants in Research on Emerging and Re-emerging Infectious Disease from the Ministry of Health, Labor and Welfare of Japan.

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.meegid.2014.08.002>.

#### References

- Ahmed, K., Batuwanthudawe, R., Chandrasena, T.G., Mitui, M.T., Rajindrajith, S., Galagoda, G., Pun, S.B., Uchida, R., Kunii, O., Moji, K., Abeysinghe, N., Nishizono, A., Nakagomi, O., 2010. Rotavirus infections with multiple emerging genotypes in Sri Lanka. *Arch. Virol.* 155, 71–75.
- Cunliffe, N.A., Ngwira, B.M., Dove, W., Nakagomi, O., Nakagomi, T., Perez, A., Hart, C.A., Kazembe, P.N., Mwansambo, C.C., 2009. Serotype G12 rotaviruses, Lilongwe, Malawi. *Emerg. Infect. Dis.* 15, 87–90.
- Dennis, A.F., McDonald, S.M., Payne, D.C., Mijatovic-Rustempasic, S., Esona, M.D., Edwards, K.M., Chappell, J.D., Patton, J.T., 2014. Molecular epidemiology of contemporary G2P[4] human rotaviruses co-circulating in a single US community: footprints of a globally transitioning genotype. *J. Virol.* 88, 3789–3801.
- Enweronu-Laryea, C.C., Sagoe, K.W., Damanka, S., Lartey, B., Armah, G.E., 2013. Rotavirus genotypes associated with childhood severe acute diarrhoea in southern Ghana: a cross-sectional study. *Virol. J.* 10, 287.
- Estes, M.K., Greenberg, H.B., 2013. Rotaviruses. In: Knipe, P.M., Howley, D.M. (Eds.), *Fields Virology*, sixth ed. Lippincott Williams & Wilkins, Philadelphia, pp. 1347–1401.
- Felsenstein, J., 1985. Confidence limits on phylogenies: an approach using the bootstrap. *Evolution* 39, 783–791.
- Ghosh, S., Varghese, V., Samajdar, S., Bhattacharya, S.K., Kobayashi, N., Naik, T.N., 2006. Molecular characterization of a porcine group A rotavirus strain with G12 genotype specificity. *Arch. Virol.* 151, 1329–1344.
- Ghosh, S., Kobayashi, N., Nagashima, S., Chawla-Sarkar, M., Krishnan, T., Ganesh, B., Naik, T.N., 2010. Full genomic analysis and possible origin of a porcine G12 rotavirus strain RU172. *Virus Genes* 40, 382–388.
- Ghosh, S., Kobayashi, N., 2011. Whole-genomic analysis of rotavirus strains: current status and future prospects. *Future Microbiol.* 6, 1049–1065.
- Jere, K.C., Mlera, L., O'Neill, H.G., Potgieter, A.C., Page, N.A., Seheri, M.L., van Dijk, A.A., 2011. Whole genome analyses of African G2, G8, G9, and G12 rotavirus strains using sequence-independent amplification and 454<sup>®</sup> pyrosequencing. *J. Med. Virol.* 83, 2018–2042.
- Khananurak, K., Vutithanachot, V., Simakachom, N., Theamboonlers, A., Chongsrisawat, V., Poovorawan, Y., 2010. Prevalence and phylogenetic analysis of rotavirus genotypes in Thailand between 2007 and 2009. *Infect. Genet. Evol.* 10, 537–545.
- Kiulia, N.M., Nyaga, M.M., Seheri, M.L., Wolfaardt, M., van Zyl, W.B., Esona, M.D., Irimu, G., Inoti, M., Gatimu, B.W., Njenga, P.K., Taylor, M.B., Nyachio, A., 2014. Rotavirus G and P types circulating in the eastern region of Kenya: predominance of G9 and emergence of G12 genotypes. *Pediatr. Infect. Dis. J.* 33, S85–S88.
- Komoto, S., Sasaki, J., Taniguchi, K., 2006. Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus. *Proc. Natl. Sci. U.S.A.* 103, 4646–4651.
- Komoto, S., Maeno, Y., Tomita, M., Matsuoka, T., Ohfu, M., Yodoshi, T., Akeda, H., Taniguchi, K., 2013. Whole genomic analysis of a porcine-like human G5P[6] rotavirus strain isolated from a child with diarrhoea and encephalopathy in Japan. *J. Gen. Virol.* 94, 1568–1575.
- Madhi, S.A., Cunliffe, N.A., Steele, D., Witte, D., Kirsten, M., Louw, C., Ngwira, B., Victor, J.C., Gillard, P.H., Cheuvart, B.B., Han, H.H., Neuzil, K.M., 2010. Effect of rotavirus vaccine on severe diarrhea in African infants. *N. Engl. J. Med.* 362, 289–298.
- Maes, P., Matthijssens, J., Rahman, M., Van Ranst, M., 2009. RotaC: a web-based tool for the complete genome classification of group A rotaviruses. *BMC Microbiol.* 9, 238.

Please cite this article in press as: Komoto, S., et al. Whole genomic analysis of human G12P[6] and G12P[8] rotavirus strains that have emerged in Kenya: Identification of porcine-like NSP4 genes. *Infect. Genet. Evol.* (2014), <http://dx.doi.org/10.1016/j.meegid.2014.08.002>

- 545 Maestri, R.P., Kaiano, J.H., Neri, D.L., Soares Lda, S., Guerra Sde, F., Oliveira Dde, S.,  
546 Farias, Y.N., Gabbay, Y.B., Leite, J.P., Linhares Ada, C., Mascarenhas, J.D., 2012.  
547 Phylogenetic analysis of probable non-human genes of group A rotaviruses  
548 isolated from children with acute gastroenteritis in Belém, Brazil. *J. Med. Virol.*  
549 84, 1993–2002.
- 550 Mascarenhas, J.D., Leite, J.P., Lima, J.C., Heinemann, M.B., Oliveira, D.S., Araújo, I.T.,  
551 Soares, L.S., Gusmão, R.H., Gabbay, Y.B., Linhares, A.C., 2007a. Detection of a  
552 neonatal human rotavirus strain with VP4 and NSP4 genes of porcine origin. *J.*  
553 *Med. Microbiol.* 56, 524–532.
- 554 Mascarenhas, J.D., Linhares, A.C., Gabbay, Y.B., Lima, C.S., Guerra Sde, F., Soares, L.S.,  
555 Oliveira, D.S., Lima, J.C., Macêdo, O., Leite, J.P., 2007b. Molecular characterization  
556 of VP4 and NSP4 genes from rotavirus strains infecting neonates and young  
557 children in Belém, Brazil. *Virus Res.* 126, 149–158.
- 558 Matthijnsens, J., Ciarlet, M., Heiman, E., Arijis, I., Delbeke, T., McDonald, S.M.,  
559 Palombo, E.A., Iturriza-Gómara, M., Maes, P., Patton, J.T., Rahman, M., Van Ranst,  
560 M., 2008. Full genome-based classification of rotaviruses reveals a common  
561 origin between human Wa-Like and porcine rotavirus strains and human DS-1-  
562 Like and bovine rotavirus strains. *J. Virol.* 82, 3204–3219.
- 563 Matthijnsens, J., Bilcke, J., Ciarlet, M., Martella, V., Bányai, K., Rahman, M., Zeller, M.,  
564 Beutels, P., Van Damme, P., Van Ranst, M., 2009. Rotavirus disease and  
565 vaccination: impact on genotype diversity. *Future Microbiol.* 4, 1303–1316.
- 566 Matthijnsens, J., Heylen, E., Zeller, M., Rahman, M., Lemey, P., Van Ranst, M., 2010a.  
567 Phylogenetic analyses of rotavirus genotypes G9 and G12 underscore their  
568 potential for swift global spread. *Mol. Biol. Evol.* 27, 2431–2436.
- 569 Matthijnsens, J., Rahman, M., Ciarlet, M., Zeller, M., Heylen, E., Nakagomi, T.,  
570 Uchida, R., Hassan, Z., Azim, T., Nakagomi, O., Van Ranst, M., 2010b.  
571 Reassortment of human rotavirus gene segments into G11 rotavirus strains.  
572 *Emerg. Infect. Dis.* 16, 625–630.
- 573 Matthijnsens, J., Ciarlet, M., McDonald, S.M., Attoui, H., Bányai, K., Brister, J.R.,  
574 Buesa, J., Esona, M.D., Estes, M.K., Gentsch, J.R., Iturriza-Gómara, M., John, R.,  
575 Kirkwood, C.D., Martella, V., Mertens, P.P., Nakagomi, O., Parreño, V., Rahman,  
576 M., Ruggeri, F.M., Saif, L.J., Santos, N., Steyer, A., Taniguchi, K., Patton, J.T.,  
577 Desselberger, U., Van Ranst, M., 2011. Uniformity of rotavirus strain  
578 nomenclature proposed by the Rotavirus Classification Working Group  
579 (RCWG). *Arch. Virol.* 156, 1397–298.
- 580 Matthijnsens, J., Van Ranst, M., 2012. Genotype constellation and evolution of  
581 group A rotaviruses infecting humans. *Curr. Opin. Virol.* 2, 426–433.
- 582 McDonald, S.M., McKell, A.O., Rippinger, C.M., McAllen, J.K., Akopov, A., Kirkness,  
583 E.F., Payne, D.C., Edwards, K.M., Chappell, J.D., Patton, J.T., 2012. Diversity and  
584 relationships of cocirculating modern human rotaviruses revealed using large-  
585 scale comparative genomics. *J. Virol.* 86, 9148–9162.
- 586 Midgley, S.E., Bányai, K., Buesa, J., Halaihel, N., Hjulsager, C.K., Jakab, F., Kaplon, J.,  
587 Larsen, L.E., Monini, M., Poljšak-Prijatelj, M., Pothier, P., Ruggeri, F.M., Steyer, A.,  
588 Koopmans, M., Böttiger, B., 2012. Diversity and zoonotic potential of rotaviruses  
589 in swine and cattle across Europe. *Vet. Microbiol.* 156, 238–245.
- 590 Mwenda, J.M., Ntoto, K.M., Abebe, A., Enweronu-Laryea, C., Amina, I., Mchomvu, J.,  
591 Kisakye, A., Mpabalwani, E.M., Pazvakavambwa, I., Armah, G.E., Seheri, L.M.,  
592 Kiulia, N.M., Page, N., Widdowson, M.A., Steele, A.D., 2010. Burden  
593 and epidemiology of rotavirus diarrhea in selected African countries: preliminary  
594 results from the African Rotavirus Surveillance Network. *J. Infect. Dis.* 202, S5-  
595 S11.
- 596 Nakagomi, T., Nakagomi, O., Dove, W., Doan, Y.H., Witte, D., Ngwira, B., Todd, S.,  
597 Duncan Steele, A., Neuzil, K.M., Cunliffe, N.A., 2012. Molecular characterization  
598 of rotavirus strains detected during a clinical trial of a human rotavirus vaccine  
599 in Blantyre, Malawi. *Vaccine* 30, A140–A151.
- 600 Ndze, V.N., Achidi, E.A., Papp, H., Kovács, E., Farkas, S., Adiogo, D., Kisfali, P., Ngeng,  
601 M.B., Abena, M.T., Martella, V., Esona, M.D., Bányai, K., 2013a. Shared G12 VP7  
602 gene among human and bovine rotaviruses detected in Cameroonian villages.  
603 *Acta Microbiol. Immunol. Hung.* 60, 21–28.
- 604 Ndze, V.N., Papp, H., Achidi, E.A., Gonsu, K.H., László, B., Farkas, S., Kisfali, P., Melegh,  
605 B., Esona, M.D., Bowen, M.D., Bányai, K., Gentsch, J.R., Odama, A.M., 2013b. One  
606 year survey of human rotavirus strains suggests the emergence of genotype G12  
607 in Cameroon. *J. Med. Virol.* 85, 1485–1490.
- 608 Nyaga, M.M., Jere, K.C., Peenze, I., Miera, L., van Dijk, A.A., Seheri, M.L., Mphahlele,  
609 M.J., 2013. Sequence analysis of the whole genomes of five African human G9  
610 rotavirus strains. *Infect. Genet. Evol.* 16, 62–77.
- 611 Oluwatoyin Japhet, M., Adeyemi Adesina, O., Famurewa, O., Svensson, L., Nordgren,  
612 J., 2012. Molecular epidemiology of rotavirus and norovirus in Ile-Ife, Nigeria:  
613 high prevalence of G12P[8] rotavirus strains and detection of a rare norovirus  
614 genotype. *J. Med. Virol.* 84, 1489–1496.
- Page, A.L., Jusot, V., Mamaty, A.A., Adamou, L., Kaplon, J., Pothier, P., Djibo, A., Manzo,  
M.L., Toure, B., Langendorf, C., Collard, J.M., Grais, R.F., 2014. Rotavirus  
surveillance in urban and rural areas of Niger, April 2010–March 2012.  
*Emerg. Infect. Dis.* 20, 573–580.
- Page, N.A., de Beer, M.C., Seheri, L.M., Dewar, J.B., Steele, A.D., 2009. The detection  
and molecular characterization of human G12 genotypes in South Africa. *J. Med.*  
*Virol.* 81, 106–113.
- Paul, S.K., Kobayashi, N., Nagashima, S., Ishino, M., Watanabe, S., Alam, M.M.,  
Ahmed, M.U., Hossain, M.A., Naik, T.N., 2008. Phylogenetic analysis of  
rotaviruses with genotypes G1, G2, G9 and G12 in Bangladesh: evidence for a  
close relationship between rotaviruses from children and adults. *Arch. Virol.*  
153, 1999–2012.
- Pongsuwanna, Y., Guntapong, R., Chiwakul, M., Tacharoenuang, R., Onvimala, N.,  
Wakuda, M., Kobayashi, N., Taniguchi, K., 2002. Detection of a human rotavirus  
with G12 and P[9] specificity in Thailand. *J. Clin. Microbiol.* 40, 1390–1394.
- Pukuta, E.S., Esona, M.D., Nkongolo, A., Seheri, M., Makasi, M., Nyembwe, M.,  
Mondonge, V., Dahl, B.A., Mphahlele, M.J., Cavallaro, K., Gentsch, J., Bowen, M.D.,  
Waku-Koumou, D., Muyembe, J.J.SURVAC Working Group, 2014. Molecular  
surveillance of rotavirus infection in the Democratic Republic of the Congo  
August 2009 to June 2012. *Pediatr. Infect. Dis. J.* 33, 355–359.
- Rahman, M., Matthijnsens, J., Yang, X., Delbeke, T., Arijis, I., Taniguchi, K., Iturriza-  
Gómara, M., Iftekaruddin, N., Azim, T., Van Ranst, M., 2007. Evolutionary  
history and global spread of the emerging G12 human rotaviruses. *J. Virol.* 81,  
2382–2390.
- Samajdar, S., Varghese, V., Barman, P., Ghosh, S., Mitra, U., Dutta, P., Bhattacharya,  
S.K., Narasimham, M.V., Panda, P., Krishnan, T., Kobayashi, N., Naik, T.N., 2006.  
Changing pattern of human group A rotaviruses: emergence of G12 as an  
important pathogen among children in eastern India. *J. Clin. Virol.* 36, 183–188.
- Samajdar, S., Ghosh, S., Dutta, D., Chawla-Sarkar, M., Kobayashi, N., Naik, T.N., 2008.  
Human group A rotavirus P[8]Hun9-like and rare OP354-like strains are circulating  
among diarrhoeic children in Eastern India. *Arch. Virol.* 153, 1933–1936.
- Santos, N., Hoshino, Y., 2005. Global distribution of rotavirus serotypes/genotypes  
and its implication for the development and implementation of an effective  
rotavirus vaccine. *Rev. Med. Virol.* 15, 29–56.
- Seheri, M., Namarude, L., Peenze, I., Netshifhehe, L., Nyaga, M.M., Ngobeni, H.G.,  
Maphalala, G., Maake, L.L., Steele, A.D., Mwenda, J.M., Mphahlele, J.M., 2014.  
Update of rotavirus strains circulating in Africa from 2007 through 2011.  
*Pediatr. Infect. Dis. J.* 33, S76–S84.
- Shinozaki, K., Okada, M., Nagashima, S., Kaiho, I., Taniguchi, K., 2004.  
Characterization of human rotavirus strains with G12 and P[9] detected in  
Japan. *J. Med. Virol.* 73, 612–616.
- Stupka, J.A., Degiuseppe, J.L., Parra, G.I. Argentinean National Rotavirus Surveillance  
Network, 2012. Increased frequency of rotavirus G3P[8] and G12P[8] in  
Argentina during 2008–2009: whole-genome characterization of emerging  
G12P[8] strains. *J. Clin. Virol.* 54, 162–167.
- Tamura, K., Stecher, G., Peterson, D., Filipksi, A., Kumar, S., 2013. MEGA6: molecular  
evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* 30, 2725–2729.
- Taniguchi, K., Urasawa, T., Kobayashi, N., Gorziglia, M., Urasawa, S., 1990. Nucleotide  
sequence of VP4 and VP7 genes of human rotaviruses with subgroup I  
specificity and long RNA pattern: implication for new G serotype specificity. *J.*  
*Virol.* 64, 5640–5644.
- Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Dugue, J., Parashar, U.D. WHO-  
coordinated Global Rotavirus Surveillance Network, 2012. 2008 estimate of  
worldwide rotavirus-associated mortality in children younger than 5 years  
before the introduction of universal rotavirus vaccination programmes: a  
systematic review and meta-analysis. *Lancet Infect. Dis.* 12, 136–141.
- Thompson, J.D., Higgins, D.G., Gibson, T.J., 1994. CLUSTAL W: improving the  
sensitivity of progressive multiple sequence alignment through sequence  
weighting, position-specific gap penalties and weight matrix choice. *Nucleic*  
*Acids Res.* 22, 4673–4680.
- Trojnar, E., Sachsenröder, J., Twardziok, S., Reetz, J., Otto, P.H., John, R., 2013.  
Identification of an avian group A rotavirus containing a novel VP4 gene with a  
close relationship to those of mammalian rotaviruses. *J. Gen. Virol.* 94, 136–142.
- Urasawa, S., Urasawa, T., Wakasugi, F., Kobayashi, N., Taniguchi, K., Lintag, I.C.,  
Saniel, M.C., Goto, H., 1990. Presumptive seventh serotype of human rotavirus.  
*Arch. Virol.* 113, 279–282.
- Wakuda, M., Nagashima, S., Kobayashi, N., Pongsuwanna, Y., Taniguchi, K., 2003.  
Serologic and genomic characterization of a G12 human rotavirus in Thailand. *J.*  
*Clin. Microbiol.* 41, 5764–5769.

615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684

Please cite this article in press as: Komoto, S., et al. Whole genomic analysis of human G12P[6] and G12P[8] rotavirus strains that have emerged in Kenya: identification of porcine-like NSP4 genes. *Infect. Genet. Evol.* (2014), <http://dx.doi.org/10.1016/j.meegid.2014.08.002>

# Production of inflammatory cytokines in response to diphtheria-pertussis-tetanus (DPT), *haemophilus influenzae* type b (Hib), and 7-valent pneumococcal (PCV7) vaccines

Yasuyo Kashiwagi<sup>1,2</sup>, Akiko Miyata<sup>3</sup>, Takuji Kumagai<sup>4</sup>, Kouji Maehara<sup>5</sup>, Eitarou Suzuki<sup>6</sup>, Takao Nagai<sup>7</sup>, Takao Ozaki<sup>8</sup>, Naoko Nishimura<sup>9</sup>, Kenji Okada<sup>9</sup>, Hisashi Kawashima<sup>2</sup>, and Tetsuo Nakayama<sup>1</sup>

<sup>1</sup>Laboratory of Viral Infection I; Kitasato Institute for Life Sciences; Tokyo, Japan; <sup>2</sup>Department of Pediatrics; Tokyo Medical University; Tokyo, Japan; <sup>3</sup>Miyata Pediatric Clinic; Tachikawa; Tokyo, Japan; <sup>4</sup>Kumagai Pediatric Clinic; Sapporo, Japan; <sup>5</sup>Maehara Pediatric Clinic; Tama, Tokyo, Japan; <sup>6</sup>Suzuki Pediatric Clinic; Ube, Yamaguchi Prefecture, Japan; <sup>7</sup>Nagai Pediatric Clinic; Takamatsu, Kagawa Prefecture, Japan; <sup>8</sup>Department of Pediatrics; Konan Kosei Hospital; Konan; Aichi Prefecture, Japan; <sup>9</sup>Department of Pediatrics; National Fukuoka Hospital; Fukuoka, Japan

**Keywords:** innate immunity, cytokine, peripheral blood mononuclear cells, PBMCs, *Haemophilus influenzae* type b T-conjugated vaccine, Hib, 7-valent pneumococcal conjugated vaccine, PCV7, Diphtheria and tetanus toxoids combined with acellular pertussis vaccine, DPT

**Abbreviations:** ASC, apoptosis-associated speck-like protein; BCG, Bacille de Calmette et Guérin; CTL, cytotoxic T lymphocytes; DPT, diphtheria and tetanus toxoids combined with acellular pertussis vaccine; G-CSF, granulocyte-colony stimulating factor; Hib, *Haemophilus influenzae* type b vaccine; IFN, interferon; IL, interleukin; IPV, inactivated polio vaccine; JEV, Japanese encephalitis vaccine; LPS, lipo-polysaccharides; MIP-1, macrophage inflammatory protein-1; MMR, measles mumps and rubella combined vaccine; MR, measles and rubella combined vaccine; NF- $\kappa$ B, nuclear factor kappa B; NLRP-3, NOD-like-receptor-family member (NLRP)-3; PBMCs, peripheral blood mononuclear cells; PCV7, 7-valent pneumococcal vaccine; PGE2, prostaglandin E2; PMNs, polymorph nuclear neutrophils; RIG-I, retinoic acid inducible gene-based-like receptors; ROX, reactive oxygen species; TLRs, Toll-like receptors; TNF- $\alpha$ , tissue necrotic factor- $\alpha$


*Haemophilus influenzae* type b (Hib) and 7-valent pneumococcal (PCV7) vaccines both became recommended in Japan in 2010. In this study, cytokine production was investigated in peripheral blood mononuclear cells (PBMCs) cultures stimulated with diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DPT), Hib, and PCV7 separately or concurrent different combinations, all as final off-the-shelf vaccines without the individual vaccine components as controls. Higher IL-1 $\beta$  levels were produced when cultures were stimulated with PCV than with DPT or Hib, and the concurrent stimulation including PCV7 enhanced the production of IL-1 $\beta$ . Although Hib induced higher levels of IL-6, no significant difference was observed in IL-6 production with the concurrent stimulation. The concurrent stimulation with Hib/PCV7 and DPT/Hib/PCV7 produced higher levels of TNF- $\alpha$  and human G-CSF. Cytokine profiles were examined in serum samples obtained from 61 vaccine recipients with febrile reactions and 18 recipients without febrile illness within 24 h of vaccination. No significant difference was observed in cytokine levels of IL-1 $\beta$ , IL-4, IL-6, IL-10, IL-12, IFN- $\gamma$ , MIP-1, TNF- $\alpha$ , and prostaglandin E2 (PGE2) in sera between the two groups. However, significantly higher levels of human G-CSF were observed in recipients with febrile illness than in those without febrile reactions. Further investigations of the significance of elevated serum G-CSF levels are required in vaccine recipients with febrile illness.

## Introduction

A long-term vaccine gap occurred in Japan from 1993 when measles mumps and rubella combined vaccine (MMR) was discontinued because of the unexpectedly high incidence of aseptic meningitis caused by mumps vaccine components.<sup>1,2</sup> Thereafter, new vaccines were not introduced until 2008.

However, many pediatric vaccines have been approved with the implementation of recommended immunization schedules in developed countries, which shows that vaccine preventable diseases need to be controlled.<sup>3-6</sup> *Haemophilus influenzae* type b conjugated with tetanus toxoid (Hib) became licensed in December 2008, and 7-valent pneumococcal conjugated with recombinant diphtheria toxoid (PCV7) vaccines in February

\*Corresponding author: Tetsuo Nakayama; Email: tetsuo-n@lisci.kitasato-u.ac.jp  
Submitted: 07/22/2013; Revised: 11/08/2013; Accepted: 11/19/2013  
<http://dx.doi.org/10.4161/hv.27264>



**Figure 1.** IL-1 $\beta$ , IL-6, TNF- $\alpha$ , and G-CSF production in PBMCs cultures stimulated with DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. PBMCs were obtained from 29 individuals and culture fluids were harvested 24 h after stimulation. Cytokine concentrations were measured using BioPlex 17 cytokine panel. Each bar represents the mean concentration ( $\bullet$ ) with 95% CI.

2010, respectively. The simultaneous administration of several vaccines was recommended by the Japanese Pediatric Association, similar to the US and EU.<sup>3,4</sup> PCV7 had relatively more adverse reactions of fever  $\geq 38^\circ\text{C}$ , swelling, tenderness at injection site, and irritability than those receiving meningococcal vaccine having the same conjugate protein.<sup>7</sup> Combination vaccine containing diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DPT), hepatitis B, and inactivated poliovirus vaccine was generally co-administered with Hib (DPT-HBV-IPV-Hib) in the EU. The incidence of fever  $\geq 38.0^\circ\text{C}$  in the concomitant administration group (DPT-HBV-IPV-Hib with PCV7) was significantly higher than that reported in the separate vaccination group, but there was no significant difference in the incidence of high fever  $\geq 39.0^\circ\text{C}$ .<sup>8,9</sup>

All effective vaccines induce acquired immunity with the development of antigen-specific antibodies and/or cell-mediated immunity, and the stimulation of innate immunity is now considered essential. Innate immunity consists of two different patterns: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and controls the T and B cells to regulate acquired immune responses.<sup>10</sup> The stimulation of innate immunity has been found to modulate the development of an acquired immune response through the production of cytokines.<sup>11-13</sup> PAMPs consist of Toll-like receptors (TLRs) and retinoic acid inducible gene-based (RIG)-like receptors, which recognize the pattern of microbes.<sup>14-16</sup> Aluminum adjuvant

induces inflammation at the injection site, and endogenous products released from damaged cells (damage or danger associated signals) stimulate DAMP, activating inflammasomes.<sup>17,18</sup> These have been shown to induce the production of inflammatory cytokine IL-1 $\beta$  from proinflammatory molecules.<sup>19</sup> DPT and PCV7 contain aluminum adjuvant and stimulate NLRP3 inflammasomes through tissue damage.<sup>19</sup> Vaccine antigens initiate innate immune response by the recognition by PAMPs at the injection site, activating dendritic cells (DCs). Antigen is processed and peptide is presented on MHC molecules (signal 1), and antigen presenting cells are migrated to the draining lymph nodes. Type I Interferon (IFN) and inflammatory cytokines enhance the expression of co-stimulatory molecules to help the recognition by T-cell (signal 2). IFN- $\gamma$ , IL-4, and IL-12 modulate the differentiation toward Th1 and Th2 responses.<sup>18</sup> The mechanisms of immunogenicity induced by aluminum adjuvant regarding whether the stimulation of NLRP3 inflammasomes is necessary or not have not yet been fully understood.<sup>18-20</sup> The activation of innate immunity by vaccines is indispensable for immunogenicity, and the enhanced production of inflammatory cytokines may be related to the occurrence of adverse events.<sup>21</sup> Vaccine-specific innate inflammatory responses are clearly important, and have not been sufficiently investigated regarding cytokine production using different vaccines.


In our previous report, aluminum-adjuvanted H5 whole virion inactivated vaccine (WIV) was licensed for adults in

Japan but induced marked febrile reactions with significantly stronger antibody responses in children. Aluminum adjuvant alone did not induce inflammatory cytokines, and H5 WIV induced IL-6, IL-17, TNF- $\alpha$ , MCP-1, IFN- $\gamma$ , and IFN- $\alpha$  in peripheral blood mononuclear cells (PBMCs) cultures. Aluminum-adjuvanted H5 WIV enhanced IL-1 $\beta$  production, with similar levels of other cytokines stimulated with H5 WIV.<sup>21</sup> In this report, cytokine profiling was investigated using PBMCs to evaluate cytokine production in response to the stimulation of DPT, Hib, and PCV7, separately and concurrent different combinations. Since the separate components of these final vaccines were not available, only the final formulated vaccines could be used as in-vitro stimulants. Serum cytokine levels were investigated in 61 vaccine recipients with febrile reactions and 18 recipients without febrile illness within 24 h of vaccination.

## Results

### Cytokine production in PBMCs stimulated with the single or different combinations of vaccines

Preliminary studies of cytokine production showed that cytokines began to be produced 6 h after the stimulation and increased until 24 h, showing the same level afterward, similar to the previous report of aluminum-adjuvanted H5N1 pandemic vaccine.<sup>22</sup> Cell viability of non-stimulation was approximately 85–90%, 70–75% for non-adjuvanted vaccines, 50–60% for aluminum-adjuvanted vaccines 24 h after stimulation. PBMCs were stimulated with marketed vaccines, and culture supernatant was collected 24 h after the stimulation. Seventeen cytokine profiles were examined in PBMCs cultures obtained from 29 subjects by stimulation of single or different combinations of DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. IL-8, MCP-1, and MIP-1 $\beta$  were produced in the control culture and showed no change with the stimulation. No significant difference was observed in the levels of IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-17, GM-CSF, or IFN- $\gamma$  in response to the single or concurrent stimulation with different combinations of vaccines. Higher levels of IL-1 $\beta$ , IL-6, G-CSF, and TNF- $\alpha$  were produced with the concurrent stimulations than with the single stimulation, and the mean values are shown with 95% confidence intervals (CI) in **Figure 1**. DPT and Hib induced similar levels of IL-1 $\beta$ , 72.9 pg/ml (95% CI: 37.2–108.5 pg/ml) and 106.9 pg/ml (95% CI: 44.0–169.9 pg/ml), respectively, and 0.34 pg/ml (95% CI: 0.11–0.58 pg/ml) was detected in the control culture. PCV7 induced higher levels of IL-1 $\beta$ , 178.5 pg/ml (95% CI: 42.1–314.9 pg/ml). DPT/Hib and DPT/PCV7 generated similar levels of IL-1 $\beta$ , 212.2 pg/ml (95% CI: 124.5–299.9 pg/ml) and 289.3 pg/ml (95% CI: 158.4–429.2 pg/ml), respectively. Hib/PCV7 and DPT/Hib/PCV7 produced significantly higher levels, 433.7 pg/ml (95% CI: 226.1–641.3



**Figure 2.** IL-1 $\beta$  production in the PBMCs of 29 individuals. PBMCs were stimulated with DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. Columns from left to right in each individual show the production of IL-1 $\beta$  measured by EIA.

pg/ml) and 510.9 (95% CI: 270.0–751.9 pg/ml), respectively. The concurrent stimulation with PCV7 induced slightly higher levels of IL-1 $\beta$ .

A mean of 4.56 pg/ml (95% CI: 1.3–7.8 pg/ml) of IL-6 was produced in the control cultures. The stimulation with Hib induced higher levels of IL-6 (4136.7 pg/ml, 95% CI: 1883.5–6389.9 pg/ml), while there was no significant difference in the production of IL-6 in response to the stimulation with DPT and PCV7, which showed a mean level of 2438 and 1872 pg/ml, respectively. The concurrent stimulation induced similar levels of IL-6, 3248–4033 pg/ml. No significant difference was observed in IL-6 production with the single or concurrent stimulation.

A mean of 3.53 pg/ml (95% CI: 1.85–5.21 pg/ml) of TNF- $\alpha$  was produced in control cultures. Hib induced higher levels of TNF- $\alpha$  in PBMCs, 880.0 pg/ml (95% CI: 406.7–1353.4 pg/ml), than DPT (mean: 183.2 pg/ml, 95% CI: 77.0–289.3 pg/ml) or PCV7 (mean: 304.5 pg/ml, 95% CI: 51.8–557.3 pg/ml). Hib/PCV7 and DPT/Hib/PCV7 produced significantly higher levels, 1833.4 pg/ml (95% CI: 788.9–2877.9 pg/ml) and 1484.3 pg/ml (95% CI: 583.3–2385.4 pg/ml), respectively.

The results of the production of G-CSF are shown. Hib induced higher levels of G-CSF than DPT or PCV7. The concurrent stimulation with DPT/Hib, DPT/PCV7, Hib/PCV7 and DPT/Hib/PCV7 induced similar levels of G-CSF, 78.55–145.51 pg/ml.

Higher levels of IL-1 $\beta$  were produced in PBMC cultures stimulated with PCV7 than with DPT or Hib, and Hib induced higher levels of IL-6 and TNF- $\alpha$ . IL-1 $\beta$  levels increased in PBMCs stimulated concurrently with Hib/PCV7 and DPT/Hib/PCV7, and similar patterns of TNF- $\alpha$  and G-CSF production were observed in PBMC cultures. No significant difference in IL-6 production was observed when cultures were stimulated separately or concurrently.

**Table 1.** Number of patients with or without febrile reactions after vaccination with a different combination of vaccines

Fever +		Fever -	
DPT/Hib/PCV7	22	DPT/Hib/PCV7	4
DPT/Hib/PCV7/IPV	4	DPT/Hib/PCV7/Rota	1
DPT/Hib/PCV7/Rota	3		
DPT/Hib/PCV7/BCG	1		
PCV7/Hib	7	PCV7/Hib	6
PCV7/Hib/Rota	4	DPT/Hib	1
PCV7/DPT	1		
PCV7	9	PCV7	4
PCV7/MR	3	DPT	2
Hib	3		
PCV/Rota	1		
PCV/IPV	1		
PCV/IPV/Rota	1		
PCV/Influenza	1		
Total	61		18

DPT, Diphtheria, tetanus toxoids, combined with acellular pertussis vaccine; Hib, *Hemophilus influenzae* type b T-conjugated vaccine; PCV7, 7-valent pneumococcal conjugated vaccine; Rota, Rotavirus vaccine; BCG, Bacillus Calmette-Guérin; MR, Measles and rubella combined vaccine; IPV, Inactivated polio vaccine.

The BioPlex assay for human 17-plex shows cytokine profiles, and the actual concentrations of cytokines should be examined by quantitative EIA. IFN- $\alpha/\beta$ , IL-1 $\beta$ , and IL-6 were re-examined using EIA. No IFN- $\alpha/\beta$  was detected in PBMCs cultures stimulated with DPT, Hib, or PCV7, and IL-1 $\beta$  and IL-6 levels were similar to those obtained by the BioPlex assay. The results of IL-1 $\beta$  production in the 29 individuals are shown in Figure 2. All subjects over 5 mo old had a DPT vaccination, whereas, very few subjects had the Hib but none had PCV7 vaccination. Higher IL-1 $\beta$  production was noted in young infants, but decreased at around 2 y old and or older, except for two subjects (4 y and 5 mo old and 5 y and 11 mo old) who recovered from aseptic meningitis. Scale-over values of > 800 pg/ml were observed in young infants by the stimulation with multiple stimulations of Hib/PCV7 and DPT/Hib/PCV7.

#### Serum cytokine profiles of vaccine recipients with or without febrile illness

Experiments with PBMCs showed that inflammatory cytokines were produced in response to the vaccine preparations, but did not reflect the situation in vivo. The next concern was whether cytokines were produced in the serum after immunization. Cytokine profiles were investigated in 61 serum samples obtained from recipients who exhibited febrile illness within 24 h of being vaccinated. Eighteen serum samples were obtained from recipients without febrile illness. These samples

were taken within 48 h of vaccination in both groups. The background of their vaccination is shown in Table 1. Based upon the data of PBMCs culture, cytokine response seemed to be different according to the number of vaccine antigens. Among 61 febrile group, 30 were immunized with three or four vaccines including DPT, Hib, and PCV7, 12 with basically two bacterial vaccines, and 19 with one to three, including one bacterial vaccine. Non-febrile group was similarly categorized. Considering the results indicating that IL-1 $\beta$ , IL-6, G-CSF, and TNF- $\alpha$  were secreted in stimulated PBMC cultures, we next investigated whether the levels of inflammatory cytokines in sera of children with febrile reaction were higher than those in sera from children that did not develop fever. The results of cytokine profiles are shown in Figure 3. Serum G-CSF levels were significantly higher in recipients with febrile illness than in those without febrile reactions. No detectable IL-1 $\beta$  was observed in sera in both febrile and non-febrile groups and no significant difference was observed in cytokine levels of IL-6 and TNF- $\alpha$  between the two groups. These results are summarized in Table 2. The mean serum levels of inflammatory cytokines IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , were 0.68, 29.44, and 13.43 pg/ml in vaccine recipients with febrile reactions after the simultaneous injection of three (DPT/Hib/PCV) or four vaccines (DPT/Hib/PCV + other vaccine), and similar levels of inflammatory cytokines were produced in vaccine recipients with febrile reactions after immunization of one or two inactivated bacterial vaccines, also similar to those in non-febrile group. Cytokine profiles of ten normal subjects without vaccination were examined and the mean titers of cytokines are also shown in Table 2. Higher levels of IL-6, IL-10, IL-12, G-CSF, IFN- $\gamma$ , and TNF- $\alpha$  were detected in both febrile and non-febrile groups after vaccination in comparison with those in normal subjects. No significant difference was observed in Th1 or Th2 cytokines (IL-4, IL-10, IL-12, and IFN- $\gamma$ ) between the two febrile and non-febrile groups. The mean G-CSF level in vaccine recipients with febrile illness was 87.24 pg/ml after three simultaneous injections, higher than those in the recipients with febrile reaction after immunization with one or two vaccines, and in the non-febrile group.

As a fever-related inflammatory protein, serum PGE2 was assayed by competitive EIA, and the results are also shown in Table 2. The mean serum PGE2 concentration was 148.62 pg/ml (95%CI: 90.7–206.5 pg/ml) in the febrile group immunized three vaccines, and there was no significant difference in PGE2 concentration between febrile and non-febrile groups.

#### Comparison of cytokine profiles of vaccine recipients with those of patients with influenza


IL-1 $\beta$ , IL-6, G-CSF, and TNF- $\alpha$  concentrations were compared with serum levels in patients with the H1N1 2009 outbreak and 18 samples from patients admitted to the hospital with acute pneumonia and 9 from outpatients (Table 3). Levels were higher in hospitalized patients than in outpatients, but this was not significant. IL-1 $\beta$  was not detected in sera obtained from outpatients and no significant difference was observed in IL-6 and TNF- $\alpha$  levels between the influenza outpatients and immunization groups with febrile or non-febrile illness after vaccination.

The IL-1 $\beta$  level was < 1pg/ml and IL-6, G-CSF and TNF- $\alpha$  levels were < 5pg/ml in the control group with no illness.

## Discussion

Currently available vaccines are categorized into live attenuated and inactivated vaccines with or without adjuvant. They induce acquired immunity: antigen-specific cytotoxic T lymphocytes (CTL) attack infected cells and antibodies prevent infections, which are modulated by innate immunity. Innate immunity consists of two different patterns, pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).<sup>10</sup> The first-line of the innate immune response depends on the TLRs expressed on dendritic cells for antigen-presenting cells, polymorph nuclear neutrophils (PMNs) and monocytes, inducing cytokines in response to the invading microorganisms.<sup>14,23,24</sup> They recognize viral, fungal, or bacterial components, in addition to replicative or non-replicative pathogens recognized by RIG like receptor, or warning signals by some adjuvants. Recognition by innate immune receptors activates the signaling cascades of IFN- $\alpha/\beta$ , and the nuclear factor kappa B (NF- $\kappa$ B)-related elevated transcription of cytokines. Cellular damage and danger signals stimulate DAMP, activating inflammasomes.<sup>17,18</sup> In this study, cell viability reduced to 50–60% in PBMCs stimulated with aluminum-adjuvanted vaccines, and aluminum based cellular damage may have these immunological stimulation. In our previous study, aluminum-adjuvanted H5N1 whole virion inactivated vaccine induced inflammatory cytokines, although aluminum adjuvant alone did not induce these cytokines. Inflammasomes consist of NLRP3 and apoptosis-associated speck-like protein (ASC), which is thought to be an adaptor molecule of NLRP-3, resulting in the recruitment of caspase. It induces the inflammatory cytokines, IL-1 $\beta$ , IL-6, and IL-18, from proinflammatory molecules.<sup>17,20</sup> Type I IFN enhanced the expression of co-stimulatory molecules recognized by CD8+ CTL cells, together with MHC I molecules and inflammatory cytokines for co-stimulatory molecules for MHC II, recognized by CD4+ cells. CD4+ cells differentiate to functionally different Th1 and Th2 cells to produce different subclass antibodies through cytokines. Thus, innate immunity modulates the acquired immunity induced by vaccinations, and effective vaccines theoretically have an impact on the innate immune system by acting as the agonists of TLRs, RIG-I, and NOD-like receptors, inducing the production of cytokines and chemokines.<sup>10-13</sup>

Innate immune systems are not fully functional at the time of birth. Human neonatal plasma showed high levels of Th2 cytokines during the first week following birth, and neonatal APCs demonstrated skewed Th2 responses.<sup>25</sup> Caron et al.<sup>26</sup> reported that the production of regulatory Th1 and Th2



**Figure 3.** Cytokine profiles of 61 individuals with febrile reactions within 24 h after immunization (upper panel) and those of 18 recipients without febrile illness (lower panel).

cytokines following the administration of TLR agonists was lower in cord blood than in adult blood. In contrast, TLR-stimulated pro-inflammatory cytokine (IL-1 $\beta$ , IL-6, and IL-8) production was markedly higher in neonates than in adults. The increased susceptibility of neonates to bacterial infections may be related to imbalanced TLR responsiveness, with enhanced pro-inflammatory cytokines and decreased regulatory cytokine production. Burl et al.<sup>27</sup> reported that most TLR agonists induced the production of TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IL-10 in cord blood. For most agonists, TLR-mediated TNF- $\alpha$  and IFN- $\gamma$  responses increased from birth to one month of age and TLR8 agonists also induced the production of Th1-polarizing cytokines. In contrast, IL-1 $\beta$ , IL-6, and IL-10 responses to most agonists were robust at birth and remained stable through to 12 mo of age in Gambian infants relative to those in developed countries.

Studies of bacterial infections suggest that bacterial lipopolysaccharides (LPS) act as TLR4 agonists, and vaccine antigens of the polysaccharides of Hib or PCV7 are considered to be TLR4 agonists.<sup>28,29</sup> DPT used in Japan is an acellular formulation with 300  $\mu$ g/ml of aluminum adjuvant and PCV7 consists of 250  $\mu$ g/ml of aluminum adjuvant. In this study of cytokine production by PBMCs and cytokine responses after immunization, significant differences were observed in cytokine induction, particularly for IL-1 $\beta$  by different vaccines and stimulation of different combinations of vaccines in PBMCs. The IL-1 $\beta$  levels were significantly higher in response to PCV7 than to DPT and this difference depended on the antigen-aluminum formulation.<sup>30</sup> IL-1 $\beta$  levels with the simultaneous stimulation with DPT and Hib were the same as those induced by PCV alone, but were higher with the concurrent stimulation including of PCV7. IL-1 $\beta$  production did not depend on the amount of aluminum adjuvant. DPT and PCV7 contain aluminum adjuvants and the concurrent stimulation with DPT and PCV7 induced higher IL-1 $\beta$  levels, but lower than those induced by PCV7 plus Hib.

**Table 2.** Cytokine profiles in vaccine recipients with or without febrile reactions

	Cytokine profile in subjects with febrile reaction after immunized with			
	≥ 3 bacterial vaccines (n = 30)	2 bacterial vaccines (n = 12)	One bacterial vaccine (n = 19)	
IL-1β	0.68 (0.36~0.99)	0.78 (0.08~1.48)	0.83 (-0.02~1.67)	
IL-4	0.41 (0.26~0.56)	0.29 (0.11~0.48)	0.35 (0.14~0.57)	
IL-6	29.44(17.35~41.53)	12.53 (6.88~18.20)	23.72 (11.53~35.90)	
IL-10	7.34 (1.97~12.71)	3.6 (0.31~6.88)	7.85 (3.04~12.66)	
IL-12	12.93 (-2.28~28.15)	6.4 (-2.61~13.07)	7.87 (1.27~14.46)	
G-CSF	87.24 (34.65~139.83)	37.41 (18.99~55.83)	39.88 (17.88~61.88)	
IFN-γ	49.95 (24.08~75.09)	42.95 (3.58~82.32)	33.26 (14.98~51.54)	
MIP-1β	66.81(41.33~92.29)	59.97 (32.55~87.38)	72.51 (27.10~117.92)	
TNF-α	13.43 (0.25~26.62)	4.86 (1.94~7.78)	11.3 (1.49~21.11)	
PGE2*	148.62 (90.7~206.5))	114.36 (68.91~159.8)	219.3 (51.49~387.2)	
	Cytokine profile in subjects without febrile illness after immunized with			Normal (n = 10)
	≥ 3 bacterial vaccines (n = 5)	2 bacterial vaccines (n = 7)	One bacterial vaccine (n = 6)	
IL-1β	1.12 (0.04~2.21)	0.52 (0.15~0.89)	1.53 (-0.86~3.92)	0.12 (0.04~0.21)
IL-4	1.32 (-0.6~3.25)	0.22 (0.04~0.4)	0.43 (0.05~0.81)	0.21 (0.09~0.32)
IL-6	13.43 (-5.05~31.91)	21.79 (5.8~37.8)	36.60 (-233.80~97)	2.55 (0.48~4.62)
IL-10	5.96 (-8.76~20.67)	3.54 (-3.62~10.7)	7.49 (-6.66~21.65)	1.58 (-0.28~3.22)
IL-12	10.5 (-15.62~36.62)	7.1 (-4.7~18.9)	15.29 (-18.848~49.43)	0.43 (0.19~0.66)
G-CSF	7.44 (2.30~12.58)	13.32 (3.7~22.9)	5.59 (0.83~10.34)	1.18 (-0.017~2.23)
IFN-γ	61.63 (-25.64~148.89)	19.7 (-16.4~55.8)	28.18 (-29.53~85.88)	5.24 (0.66~9.82)
MIP-1β	113.06 (-116.83~342)	91.7 (52.8~130.5)	111.73 (-0.41~223.86)	48.99 (32.19~65.80)
TNF-α	4.68 (-0.03~9.38)	11.75 (-14.8~38.3)	36.36 (-6.66~79.39)	1.35 (0.11~2.59)
PGE2*	329.5 (-43.8~702.4)	170.5 (114.3~226.8)	381.13 (54.66~707.6)	Not tested

Febrile illness was observed within 24 h after immunization in 61 subjects: three bacterial vaccines with or without other vaccine (n = 30), two bacterial vaccines with or without other vaccine (n = 12), and single bacterial vaccine with or without other vaccine (n = 19). Eighteen serum samples were obtained from whom no febrile illness was observed within 24 h after immunization: three bacterial vaccines with or without other vaccine (n = 5), two bacterial vaccines with or without other vaccine (n = 7), and single bacterial vaccine with or without other vaccine (n = 6). Ten sera were obtained from normal healthy infants aged 4–15 mo of age. IL-1β, IL-4, IL-6, IL-10, IL-12, G-CSF, IFN-γ, MIP-1β, and TNF-α were assayed by Bio-Plex human 17-plex. PGE2\* was assayed with the competitive EIA kit. Mean serum concentrations of cytokines are shown with 95% CI in parentheses.

**Table 3.** Comparison of cytokine profiles of acute phase sera obtained from admitted patients or outpatients with H1N1 pandemic 2009 influenza

Influenza	IL-1β	IL-6	G-CSF	TNF-α
Admitted	19.44	35.93	12.44	16.09
95% CI	0–54.29	19.19–52.66	7.47–17.41	3.67–28.50
Outpatients	0.8	19.5	6.26	6.55
95% CI	0–2.06	1.54–37.45	3.02–9.49	1.10–11.97

Hib induced high levels of IL-6 and no significant difference was observed in IL-6 production among the different combinations of vaccines. Hib induced higher levels of TNF-α than any other single stimulation, whereas PCV7/Hib or all three vaccines together produced higher levels than the others. In this study, there are several limitations; vaccine antigens and different backgrounds of donors' age probably related to the immunization history. PBMCs were stimulated with final vaccine products, which contain adjuvants, preservatives, and stabilizers besides vaccine antigens. The unavailability of components of each vaccine resulted in the limitation that in-vitro stimulation

profiles could not be attributable to each vaccine antigen for each vaccine. These have some possibilities to influence the cytokine production in response to aluminum antigen, but the purpose of the study is to know the response to the vaccine formulations after immunization of vaccines.

PBMCs obtained from young infants produced large amounts of IL-1β, and higher levels of IL-1β, TNF-α, and G-CSF were produced when stimulated with two or three combinations of inactivated bacterial vaccines. Febrile illness developed mostly 12–16 h after vaccination and disappeared within 24–48 h. Sixty-one serum samples were obtained from febrile group and 18



from non-febrile group, and the detection of higher amounts of inflammatory cytokines was suspected. However, no significant difference was observed in cytokine profiles irrespective of febrile illness within 24 h of vaccination and no IL-1 $\beta$  was detected. Influenza is a common infectious disease with an abrupt onset of febrile illness and is a potent inducer of cytokines.<sup>15,31</sup> Compared with the acute phase of an influenza infection, cytokine profiles after vaccination were similar to those in mild-moderate outpatients infected with the 2009 pandemic strain. Higher IL-1 $\beta$  levels were observed in sera obtained from seriously ill patients that had been hospitalized, but no significant difference was noted. All effective vaccines induce the production of cytokines or chemokines, which modulate immunogenicity and are also involved in inducing adverse events, such as systemic febrile illness and immunotoxicity.<sup>21,32,33</sup> In this standpoints, IL-6, IL-10, IL-12, G-CSF, IFN- $\gamma$ , and TNF- $\alpha$  were detected in both febrile and non-febrile groups after vaccination in comparison with those in normal subjects. Some cytokines might be associated with febrile adverse events, and others to immunogenicity, although this is not yet determined. Kamgang et al.<sup>34</sup> suggested IL-1 $\beta$  as a biomarker of vaccine immunotoxicity. When a vaccine is administered through an intramuscular or subcutaneous route, the antigen is transported from the muscle tissue to the regional lymph nodes, where immune responses occur. Since the vaccine antigen does not appear directly in blood, an experiment in which PBMCs were stimulated with vaccine antigen did not necessarily reflect the in vivo responses following vaccination. Although higher levels of cytokines were expected in the sera of patients with febrile reactions, the inflammatory cytokine profiles of febrile recipients were not different from those of recipients without febrile illness. IL-1 $\beta$  is known to be a strong stimulant of oxidative stress, resulting in COX-2 stimulation and prostaglandin E2 (PGE2) production. These have been clearly related to acute or chronic inflammatory conditions. Subsequent responsiveness to cytokines may be involved in febrile illness, such as PGE2 or cytokine receptors.<sup>35,36</sup> In this study, cytokine profiles were also investigated in patients with influenza between hospitalized and outpatients groups. However, no significant difference was observed between the groups, because extremely serious patients were not included in the hospitalized patient group. Inflammatory cytokine profiles after vaccination were similar to the outpatient group infected with the influenza virus.

It was very hard to obtain the sera especially from non-febrile group (n = 18) within 24–48 h after immunization. From the results of cytokine production by PBMCs (Fig. 1) when stimulated with single or different combinations, 61 subjects with febrile reactions were categorized into three subgroups: 30 were basically immunized with three vaccines DPT/Hib/PCV7, 12 with basically two bacterial vaccines (PCV7/Hib, and PCV7/DPT) and 19 with including one bacterial vaccine. Non-febrile group was similarly categorized. Therefore, the limitation of the study was too small number of the subjects to make relevant statistical comparisons. Several individuals had an additional vaccine (IPV, Rota, BCG, influenza, or MR) besides three inactivated bacterial vaccines. These additional vaccines might affect the cytokine production. But, these live viral vaccines rarely cause febrile

reaction within 24 h after vaccination. Cytokine production was examined in PBMCs culture stimulated with IPV, influenza, and MR vaccines and very low levels of inflammatory cytokines were produced (data not shown). Therefore, additional simultaneous immunization supposed to have little influence on cytokine induction in sera.

In vaccine recipients, only human G-CSF was higher in vaccine recipients with febrile reactions and was also produced in PBMCs stimulated concurrently with two or three inactivated bacterial vaccines. G-CSF acts to mobilize and recruit neutrophils to the site of inflammation from the marginal pool.<sup>37</sup> The initial response at the injected site was the migration of neutrophils and monocytes with increased local cytokine production of G-CSF and IL-5 in experimental mouse model.<sup>38</sup> Neutrophils migrated to the injection site of the aluminum-containing vaccine and caused neutrophil extracellular traps, resulting in the degranulation of neutrophil substances.<sup>39</sup> Aluminum adjuvants induced reactive oxygen species (ROX), which caused increased the production of prostaglandin.<sup>40,41</sup> But, in this study, there was no significant difference in PGE2 concentrations in sera obtained from febrile and non-febrile groups.

A recent concept in vaccine development is the vaccine immune-network because so many genes are involved in the immunogenicity of vaccines: immune effector genes, cytokine and cytokine receptor genes, and the interaction of their transcripts.<sup>42–44</sup> Individual immunogenicity, low responders to some vaccines, may depend on a dysfunction in the immune regulatory network and, in a reflection of immunotoxicity, racial and individual differences are suspected in clinical adverse reactions. Further investigations of the significance of elevated serum G-CSF levels are required in vaccine recipients with febrile illness.

## Materials and Methods

### Study design and subjects

A total of 29 healthy children without any immunological disorders were enrolled in this study of cytokine production in PBMCs cultures (n = 29; 15 males and 14 females). They were admitted to Tokyo Medical College Hospital due to minor respiratory infections or clinical tests of liver or kidney biopsy (average 34 mo of age ranged from 2 mo to 7 y and 2 mo), and blood samples were collected just before discharge after the recovery of illness. Informed consent was obtained from their parents. PBMCs were obtained by centrifugation (Ficoll-Paque™ Plus #17–5442–02, GE Healthcare Bio-science), which was subjected within three hours after taking heparinized venous blood. PBMCs were adjusted to  $5 \times 10^5$  cells in 500  $\mu$ l of RPMI 1640 medium supplemented with 5% FBS and adequate antibiotics in a 48-well plate. Cultures were stimulated with 50  $\mu$ l of vaccine preparations and the culture supernatant was harvested 24 h later. Samples were stocked at  $-80$  °C until Bio-Plex cytokine assay. This study protocol was reviewed and approved by the Ethics Committee of Tokyo Medical University, Tokyo, Japan.

### Vaccine antigens

DPT (Kitasato), Hib (Sanofi Pasteur), and PCV7 (Pfizer) were purchased commercially. A volume of 50  $\mu$ l was used for

the stimulation of a single vaccine or different combinations of DPT/Hib, DPT/PCV7, Hib/PCV7, and DTP/Hib/PCV7. DPT and PCV7 have aluminum adjuvant at the concentration of 300 ug/ml and 250 ug/ml, respectively, and Hib does not contain aluminum.

#### Serum samples

Serum samples were obtained from 61 vaccine recipients who had febrile illness >37.5 °C within 24–48 h after a single- or simultaneous multi-vaccine administration and the details of the immunization are shown in Table 1: DPT/Hib/PCV7 (22 cases), DPT/Hib/PCV/IPV (4 cases), DPT/Hib/PCV7/Rota (3 cases), DPT/Hib/PCV7/BCG (1 case), PCV7/Hib (7 cases), PCV7/Hib/Rota (4 cases), PCV7/DPT (1 case), PCV7 (9 cases), PCV7/MR (3 cases), Hib (3 cases), and the remaining 4 cases were of a different combination of PCV7 and others. Febrile reactions were observed mainly after immunization with PCV7 and concurrent immunization including PCV7. Serum samples were also obtained within 24–48 h from 18 recipients without febrile reactions: DPT/Hib/PCV7 (4 cases), DPT/Hib/PCV7/Rota (1 case), PCV7/Hib (6 cases), DPT/Hib (1 case), PCV7 (4 cases), DPT (2 cases). For the control subjects without vaccination, serum samples were obtained from ten normal healthy subjects aged < 1–3 y old. Serum cytokine profiles were examined by Bio-Plex and the experimental protocol was approved by the Ethics Committee of Kitasato Institute. Serum samples were collected after obtaining informed consent.

#### References

1. Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuohara K, Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. *Lancet* 1995; 346:701-2; PMID:7658837; [http://dx.doi.org/10.1016/S0140-6736\(95\)92311-X](http://dx.doi.org/10.1016/S0140-6736(95)92311-X)
2. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. *Pediatr Infect Dis J* 1991; 10:209-13; PMID:2041668; <http://dx.doi.org/10.1097/00006454-199103000-00008>
3. Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage, 2010. *MMWR Morb Mortal Wkly Rep* 2011; 60:1520-2; PMID:22071590
4. Duclos P, Okwo-Bele JM, Gacic-Dobo M, Cherian T. Global immunization: status, progress, challenges and future. *BMC Int Health Hum Rights* 2009; 9(Suppl 1):S2; PMID:19828060; <http://dx.doi.org/10.1186/1472-698X-9-S1-S2>
5. Dennehy PH. Active immunization in the United States: developments over the past decade. *Clin Microbiol Rev* 2001; 14:872-908; PMID:11585789; <http://dx.doi.org/10.1128/CMR.14.4.872-908.2001>
6. Plotkin SA. Vaccines: the fourth century. *Clin Vaccine Immunol* 2009; 16:1709-19; PMID:19793898; <http://dx.doi.org/10.1128/CVI.00290-09>
7. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. *Eur J Pediatr* 2002; 161(Suppl 2):S127-31; PMID:12494258; <http://dx.doi.org/10.1007/s00431-002-1064-z>
8. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. *Vaccine* 2008; 26:3142-52; PMID:18502545; <http://dx.doi.org/10.1016/j.vaccine.2007.11.096>

9. Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Chevart B, Holmes SJ; 085 Study Investigators. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a *Haemophilus influenzae* type b conjugate vaccine. *J Pediatr* 2007; 151:43-9, e1-2; PMID:17586189; <http://dx.doi.org/10.1016/j.jpeds.2007.02.013>
10. Stegrist CA. Vaccine immunology. *Vaccines* 6th edition, edited by Plotkin SA, Orenstein WA, Offit PA, Philadelphia, Elsevier Saunders, 2013, pp14-32.
11. Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. *Pediatr Res* 2009; 65:98R-105R; PMID:19918215; <http://dx.doi.org/10.1203/PDR.0b013e31819f195d>
12. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. *Immunity* 2010; 33:464-78; PMID:21029958; <http://dx.doi.org/10.1016/j.immuni.2010.10.007>
13. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, et al. Programming the magnitude and persistence of antibody responses with innate immunity. *Nature* 2011; 470:543-7; PMID:21350488; <http://dx.doi.org/10.1038/nature09737>
14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006; 124:783-801; PMID:16497588; <http://dx.doi.org/10.1016/j.cell.2006.02.015>
15. Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. *Expert Rev Vaccines* 2010; 9:1315-24; PMID:21087109; <http://dx.doi.org/10.1586/erv.10.118>

16. Ichinohe T, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. *Expert Rev Vaccines* 2008; 7:1435-45; PMID:18980544; <http://dx.doi.org/10.1586/14760584.7.9.1435>
17. Schroder K, Tschopp J. The inflammasomes. *Cell* 2010; 140:821-32; PMID:20303873; <http://dx.doi.org/10.1016/j.cell.2010.01.040>
18. Saïd-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. *Biomed J* 2012; 35:437-49; PMID:23442356; <http://dx.doi.org/10.4103/2319-4170.104408>
19. Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med* 2008; 205:869-82; PMID:18362170; <http://dx.doi.org/10.1084/jem.20071087>
20. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. *Eur J Immunol* 2010; 40:638-42; PMID:20201020; <http://dx.doi.org/10.1002/eji.200940039>
21. Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. *Toxicol Lett* 2011; 203:97-105; PMID:21392560; <http://dx.doi.org/10.1016/j.toxlet.2011.03.001>
22. Nakayama T, Kashiwagi Y, Kawashima H, Kumagai T, Ishii KJ, Ihara T. Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions. *Vaccine* 2012; 30:3885-90; PMID:22507655; <http://dx.doi.org/10.1016/j.vaccine.2012.04.004>
23. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. *Immunol Rev* 2009; 227:221-33; PMID:19120487; <http://dx.doi.org/10.1111/j.1600-065X.2008.00731.x>

#### Cytokine assay

Culture supernatants and serum samples were subjected to Bio-Plex Pro™ Human Cytokine Assay 17-plex, using Bio-Plex 200 (GI17plex panel #M50-00031YV, Bio-Rad,). IFN- $\alpha$ , IL-1 $\beta$ , and IL-6 concentrations were measured using EIA kits, (Verikine human IFN- $\alpha/\beta$  serum sample ELISA kit #46100, pbl interferon source), (Quantikine human IL-1 $\beta$  EIA kit#DLB50, R&D Systems), and (Quantikine IL-6 EIA kit #D6050, R&D Systems), following the instruction manuals. Prostaglandin E2 was measured by competitive EIA (Prostaglandin E2 EIA Kit #KGE004B, R&D Systems).

#### Statistical analysis

Differences between groups were analyzed using the Mann-Whitney U-test or chi-square test, and a significant difference was defined as  $P < 0.05$ , using Statcel software (OMS, Saitama, Japan).


#### Disclosure of Potential Conflicts of Interest

All authors have no conflict of interest regarding this study.

#### Acknowledgments

This study was supported by Research on Regulatory Science of Pharmaceuticals and Medical Devices Grants, and funding for Research on the Accumulation of Evidence for Effective Vaccine Use and Vaccine Policy, from the Ministry of Health, Labour and Welfare.

24. Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ. Innate and adaptive immune responses to viral infection and vaccination. *Curr Opin Virol* 2011; 1:226-32; PMID:22440781; <http://dx.doi.org/10.1016/j.coviro.2011.07.002>
25. Saito S. Cytokine network at the feto-maternal interface. *J Reprod Immunol* 2000; 47:87-103; PMID:10924744; [http://dx.doi.org/10.1016/S0165-0378\(00\)00060-7](http://dx.doi.org/10.1016/S0165-0378(00)00060-7)
26. Caron JE, La Pine TR, Augustine NH, Martins TB, Hill HR. Multiplex analysis of toll-like receptor-stimulated neonatal cytokine response. *Neonatology* 2010; 97:266-73; PMID:19955831; <http://dx.doi.org/10.1159/000255165>
27. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, Philbin VJ, Mancuso C, Kampmann B, Whittle H, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. *PLoS One* 2011; 6:e18185; PMID:21533209; <http://dx.doi.org/10.1371/journal.pone.0018185>
28. Mogensen TH, Paludan SR, Kilian M, Østergaard L. Live *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. *J Leukoc Biol* 2006; 80:267-77; PMID:16731773; <http://dx.doi.org/10.1189/jlb.1105626>
29. Latz E, Franko J, Golenbock DT, Schreiber JR. *Haemophilus influenzae* type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. *J Immunol* 2004; 172:2431-8; PMID:14764714
30. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity* 2010; 33:492-503; PMID:21029960; <http://dx.doi.org/10.1016/j.immuni.2010.10.002>
31. Song BM, Kang YM, Kim HS, Seo SH. Induction of inflammatory cytokines and toll-like receptors in human normal respiratory epithelial cells infected with seasonal H1N1, 2009 pandemic H1N1, seasonal H3N2, and highly pathogenic H5N1 influenza virus. *Viral Immunol* 2011; 24:179-87; PMID:21668359; <http://dx.doi.org/10.1089/vim.2010.0125>
32. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants--a balance between toxicity and adjuvanticity. *Vaccine* 1993; 11:293-306; PMID:8447157; [http://dx.doi.org/10.1016/0264-410X\(93\)90190-9](http://dx.doi.org/10.1016/0264-410X(93)90190-9)
33. Gribble EJ, Sivakumar PV, Ponce RA, Hughes SD. Toxicity as a result of immunostimulation by biologics. *Expert Opin Drug Metab Toxicol* 2007; 3:209-34; PMID:17428152; <http://dx.doi.org/10.1517/17425255.3.2.209>
34. Kamgang RK, Ramos I, Rodrigues Duarte L, Ghielmetti M, Freudenberg M, Dahinden C, Padovan E. Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists. *Med Microbiol Immunol* 2008; 197:369-79; PMID:18283493; <http://dx.doi.org/10.1007/s00430-008-0081-6>
35. Bartfai T, Conti B. Fever. *ScientificWorldJournal* 2010; 10:490-503; PMID:20305990; <http://dx.doi.org/10.1100/tsw.2010.50>
36. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. *J Endotoxin Res* 2004; 10:201-22; PMID:15373964
37. Furze RC, Rankin SM. Neutrophil mobilization and clearance in the bone marrow. *Immunology* 2008; 125:281-8; PMID:19128361; <http://dx.doi.org/10.1111/j.1365-2567.2008.02950.x>
38. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. *Vaccine* 2011; 29:1812-23; PMID:21215831; <http://dx.doi.org/10.1016/j.vaccine.2010.12.090>
39. Munks MW, McKee AS, Macleod MK, Powell RL, Degen JL, Reisdorph NA, Kappler JW, Marrack P. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. *Blood* 2010; 116:5191-9; PMID:20876456; <http://dx.doi.org/10.1182/blood-2010-03-275529>
40. Pang T, Wang J, Benicky J, Sánchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1 $\beta$  partly through the JNK/c-Jun and NADPH oxidase pathways. *J Neuroinflammation* 2012; 9:102; <http://dx.doi.org/10.1186/1742-2094-9-102>; PMID:22642771
41. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, Aritake K, Urade Y, Morimoto Y. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. *Immunity* 2011; 34:514-26; PMID:21497116; <http://dx.doi.org/10.1016/j.immuni.2011.03.019>
42. Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. *Vaccine* 2008; 26:6183-8; PMID:18598732; <http://dx.doi.org/10.1016/j.vaccine.2008.06.057>
43. Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? *PLoS Pathog* 2011; 7:e1002344; PMID:22241978; <http://dx.doi.org/10.1371/journal.ppat.1002344>
44. Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines. *Immunol Rev* 2011; 239:197-208; PMID:21198673; <http://dx.doi.org/10.1111/j.1600-065X.2010.00971.x>



# Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines



Yasuyo Kashiwagi<sup>a</sup>, Mika Maeda<sup>b</sup>, Hisashi Kawashima<sup>a</sup>, Tetsuo Nakayama<sup>b,\*</sup>

<sup>a</sup> Department of Pediatrics, Tokyo Medical University, Tokyo 160-0023, Japan

<sup>b</sup> Kitasato Institute for Life Sciences, Laboratory of Viral Infection, Tokyo 108-8641, Japan

## ARTICLE INFO

### Article history:

Received 20 January 2014

Received in revised form 24 March 2014

Accepted 2 April 2014

Available online 24 April 2014

### Keywords:

Intramuscular injection

Muscle contracture

Subcutaneous injection

Aluminum adjuvant

Monophosphoryl lipid A (MPL)

Cytokines

## ABSTRACT

Aluminum-adjuvanted vaccines are administered through an intramuscular injection (IM) in the US and EU, however, a subcutaneous injection (SC) has been recommended in Japan because of serious muscle contracture previously reported following multiple IMs of antibiotics. Newly introduced adjuvanted vaccines, such as the human papillomavirus (HPV) vaccines, have been recommended through IM. In the present study, currently available vaccines were evaluated through IM in mice. Aluminum-adjuvanted vaccines induced inflammatory nodules at the injection site, which expanded into the intra-muscular space without any muscle degeneration or necrosis, whereas non-adjuvanted vaccines did not. These nodules consisted of polymorph nuclear neutrophils with some eosinophils within the initial 48 h, then monocytes/macrophages 1 month later. Inflammatory nodules were observed 6 months after IM, had decreased in size, and were absorbed 12 months after IM, which was earlier than that after SC. Cytokine production was examined in the injected muscular tissues and AS04 adjuvanted HPV induced higher IL-1 $\beta$ , IL-6, KC, MIP-1, and G-CSF levels in muscle tissues than any other vaccine, but similar serum cytokine profiles were observed to those induced by the other vaccines. Currently available vaccines did not induce muscular degeneration or fibrotic scar as observed with muscle contracture caused by multiple IMs of antibiotics in the past.

© 2014 Elsevier Ltd. All rights reserved.

## 1. Introduction

All vaccines have been administered through a subcutaneous injection (SC) in Japan, whereas aluminum-adjuvanted vaccines are administered through an intramuscular injection (IM) without any serious reactions in the EU, US, and many other countries [1]. IM was prohibited in Japan because serious muscle contracture was reported with multiple IMs of antibiotics with or without antipyretics in the 1960s. The first case of the muscle contracture was reported by an orthopedic surgeon in 1947, and may have been caused by IM of antibiotics. The number of these cases increased and several regional accumulations of patients were reported, especially in Yamanashi prefecture, where legal action was taken. All cases had multiple IMs of antibiotics with or without antipyretics, but not with vaccines. The Japanese Orthopedic Association

announced the Precaution in 1976 that muscle contracture was mainly caused by IM of antibiotics and that pediatricians should refrain from unnecessary IM. Thereafter, an Investigational Committee on Muscle Contracture was established by the Japanese Pediatric Association, which announced the following comments in 1977 [2]:

- 1) Muscle contracture was reported in the quadriceps, deltoids, and buttocks, and no site was safe for IM.
- 2) Muscle contracture was reported in all age groups, not just in young infants.
- 3) The indication of IM was extremely rare.
- 4) Informed consent had to be obtained from patients or their guardian in cases in which IM was required.

The histopathological findings obtained from the muscle tissues of the patients revealed the infiltration of inflammatory cells, degeneration of muscle cells, necrosis, fibrosis, and scar formation, which were similar to those observed in experimental animals following IM of various antibiotics [3–5]. IM was

\* Corresponding author at: Shirokane 5-9-1, Minato-ku, Tokyo 108-8641, Japan. Tel.: +81 3 5791 6269; fax: +81 3 5791 6130.

E-mail address: [tetsuo-n@lisci.kitasato-u.ac.jp](mailto:tetsuo-n@lisci.kitasato-u.ac.jp) (T. Nakayama).

subsequently prohibited for all medicinal procedures except the administration of immunoglobulin preparations. All vaccines were administered through SC, and the Committee on Muscle Contraction also suggested that all medicinal preparations for IM had to be histopathologically examined in the muscle tissues of experimental animals to assess the damage to muscle tissue [2].

Serious local reactions were previously reported following immunization with diphtheria and tetanus toxoids combined with the acellular pertussis vaccine (DPT) containing an aluminum adjuvant, and the precise mechanisms underlying local reactivity and immunogenicity have not fully elucidated [6–8]. In addition to a conventional aluminum adjuvant, a new vaccine containing monophosphoryl lipid A (MPL) was introduced [9]. Aluminum has been used as an adjuvant for a long time because it prolongs the retention of adsorbed antigens at the injection site (depot effect), however, recent findings on innate immunity have indicated that aluminum adjuvants initiate primary immune-stimulation in the innate immune system [10,11]. Innate immunity consists of two different patterns: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). All effective vaccines stimulate the innate immune system to produce cytokines or chemokines for the development of acquired immune responses through the expression of costimulatory molecules [12–14]. These reactions start in the early phase following the injection: therefore an investigation of local reactions following a vaccination appears to be warranted to better understand the safety and immunogenicity of vaccines [12,15,16].

*Haemophilus influenzae* type b (Hib) was introduced in Japan in 2008, 7-valent pneumococcal (PCV7) and human papillomavirus (HPV) vaccines in 2010 [17]. These newly introduced vaccines are administered through IM in other countries. However, only HPV vaccines are recommended through IM, as is stated on the package inserts. Vaccination against HPV has been associated with a chronic pain syndrome in Japan, although a causal relationship has not been established [18]. All routine vaccines, including newly introduced ones, have not been examined to assess the safety of IM administration: therefore, histopathological findings and local cytokine production were investigated in the present study using current available inactivated vaccines.

## 2. Materials and methods

### 2.1. Vaccines

All routine inactivated vaccines were examined. DPT (Kitasato Institute, Japan), Hib (Sanofi Pasteur, France), PCV7 (Pfizer, USA), the Japanese Encephalitis vaccine (JEV) (Biken, Japan), seasonal influenza split vaccine (Kitasato Institute, Japan), 4-valent HPV (Gardasil: MSD, USA), and 2-valent HPV (Cervarix: GSK, Belgium) were purchased commercially.

### 2.2. Experimental design

Four-week-old BALB/c mice were purchased from Charles River, US. All vaccines were administered in 100  $\mu$ l volume through IM in the left quadriceps muscle in four mice for each vaccine (1/5 volume of human dose) and phosphate-buffered saline (PBS) at the right quadriceps muscle for the control. Muscle tissues were examined 1 month after a single injection to compare histological findings by different vaccine preparations. Mice were immunized with three doses of DPT through IM in the same left quadriceps, or through SC in the back of the neck, to compare pathological findings through IM and SC. Injection sites were examined 1, 3, 6, 9, and 12 months after the injection to assess local reactions. Sera were also obtained to compare serological responses.

To assess cytokine responses and histological findings at very early phase following the injection, quadriceps muscle tissues and serum samples were obtained pre, 3, 6, 24, and 48 h after a single injection of DPT, Hib, PCV7, JEV, Cervarix, and Gardasil in three mice for each point. PBS was injected in the opposite quadriceps as the control.

### 2.3. Histological examinations

Quadriceps muscle tissues were fixed with 10% phosphate-buffered formalin and decalcified in PBS before embedding in paraffin. Muscle and subcutaneous tissues were stained with hematoxylin and eosin (HE) using a conventional procedure. Lumogallion staining was performed and aluminum compounds were visualized through confocal microscopy [19]. Macrophages were stained with antibodies against F4/80 (a rat monoclonal antibody against mouse F4/80, AbD Serotec, USA), iNOS (polyclonal rabbit anti-iNOS/NOS type II, BD, USA), and arginase I (rabbit polyclonal antibody against human arginase, Santa Cruz, USA) [20–22].

### 2.4. Cytokine productions

Quadriceps muscles were harvested, cut into small pieces, and homogenized with 2 ml of RPMI supplemented with 1% protease inhibitor (nacalai tesque, Kyoto, Japan) using Bio Masher II (Nippi, Tokyo, Japan). The muscle homogenate was centrifuged, filtrated through a 0.45  $\mu$ m filter, and subjected to a cytokine assay. IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-10, Eotaxin, G-CSF, KC, MCP-1, and TNF- $\alpha$  were measured using the BioPlex mouse cytokine panel (BioPlex, Bio-Rad Laboratories, USA). The local production of cytokines was expressed as the ratio of the cytokine concentration at the injected site to that at the opposite site injected with PBS, and the mean of three mice was shown for each cytokine.

### 2.5. Statistical analyses


Differences between the groups were analyzed using Cochran–Cox method and a significant difference was defined as  $p < 0.05$ , using StatMate software (ATMS, Tokyo).

## 3. Results

### 3.1. Histological findings 1 month after the single dose injection

Hib, influenza, and JEV do not contain aluminum adjuvant. The DPT vaccine consists of 300  $\mu$ g/ml of aluminum, PCV 250  $\mu$ g/ml, Gardasil 450  $\mu$ g/ml, and Cervarix contains 1.0 mg/ml together with 100  $\mu$ g/ml of monophosphoryl lipid A (MPL) adjuvant. Histological findings following IM immunization are shown in Fig. 1. Histopathological findings differed in muscle tissues injected with aluminum-adjuvanted or non-adjuvanted vaccines. No significant difference was observed in the pathological findings obtained from tissues injected with non-adjuvanted JEV vaccine. However, one of the three mice injected with Hib exhibited small localized focal inflammatory reactions with the infiltration of inflammatory and myogenic cells. Similar findings were observed in one of the four mice immunized with the influenza vaccine. Non-adjuvanted vaccines induced no significant pathological differences or small localized inflammatory reactions.


Aluminum-adjuvanted vaccines induced inflammatory nodules with the infiltration of inflammatory cells or macrophages at the marginal lesions. Inflammatory nodules spread into muscle bundle spaces without the degeneration of or atrophic changes to muscle cells. Infiltrating cells were characterized as macrophages: ballooned cytoplasm with peripherally localized nucleus. Lumogallion staining was performed to visualize the aluminum adjuvant




**Fig. 1.** Histological findings of HE staining 1 month after the inoculation with aluminum - adjuvanted and non-adjuvanted vaccines. DPT, PCV7, HPV Gardasil, and HPV Cervarix were used as aluminum-adjuvanted vaccines (Alum+). Hib, JEV, and seasonal influenza split vaccines were used as non-adjuvanted vaccines (Alum-). Three or four mice were inoculated through IM and the quadriceps muscles were removed 1 month after the injection.

and the results are shown in Fig. 2. No aluminum positive cells were observed in muscle tissues injected with Hib, or in the control. Weak staining was observed in the inflammatory nodules in muscle tissues injected with DPT, PCV7, and Gardasil. Aluminum

was homologously visualized in the inflammatory nodules of muscle tissue injected with Cervarix. Aluminum was engulfed in the cytoplasm of ballooned macrophages, resulting in macrophagic nodules.



**Fig. 2.** Aluminum staining 1 month after the inoculation of vaccines. The results of Lumogallion staining are shown 1 month after the inoculation with DPT, PCV7, HPV Gardasil, and HPV Cervarix. Regarding the control, the results of phosphate-buffered saline (PBS) and Hib (non-aluminum) are shown.



**Fig. 3.** Characteristics of inflammatory cells in the inflammatory nodules, inflammatory nodules were observed after the inoculation with aluminum-adsorbed vaccines. The results of HE staining and immuno-staining with F4/80, iNOS, and arginase I are shown after the inoculation with DPT, HPV Gardasil, and HPV Cervarix.

Histological findings following IM of Cervarix, which contains MPL, appeared to be different from those in muscle tissues injected with DPT, PCV7, and Gardasil, in which aluminum is used as an adjuvant at different concentrations. Macrophages were stained with F4/80, iNOS, and arginase I, and the results are shown in Fig. 3. The inflammatory nodules were investigated 1 month after IM. Migrated cells located at the marginal lesions of inflammatory nodules in muscle tissue injected with DPT and Gardasil were stained with F4/80, iNOS, and arginase I. However, those infiltrated after IM of Cervarix were positive for F4/80 and weakly positive for arginase I, but not for iNOS.


### 3.2. Comparison of histological findings through SC and IM

No histopathological differences were observed following IM of non-adsorbed vaccines. Aluminum-adsorbed vaccines induced similar histological changes, except for Cervarix. The DPT vaccine is a basic vaccine for young infants and is administered through SC, which is recommended by the immunization law in Japan. Histological changes were compared 1, 3, 6, 9, and 12 months after IM or SC of three doses with a four-week interval in three mice for each group. Histological changes 1 month after the three injections were similar to those 1 month after the single dose, as shown in Fig. 1, and those observed 3, 6, and 9 months after immunization are shown in Fig. 4. Inflammatory nodules were relatively larger 3 months after IM than those after SC, but became smaller 6 months after IM. Histological findings of nodules after IM were similar to those after SC, and their sizes were the same until 9 months after the injection.

Histopathological changes were compared 1 year after SC and IM of three doses of DPT and the results are shown in Fig. 5. Three mice were examined: inflammatory nodules remained in two mice after SC but not in one mouse. Although IM initially induced large inflammatory nodules, this appeared to be absorbed earlier than SC, and inflammatory nodule remained in one among three mice through IM administration.

### 3.3. Production of cytokines at the injection site and serum cytokine profiles

All effective vaccines have stimulatory signals that activate the innate immune response to induce acquired immunity through the production of cytokines or chemokines. These vaccines are associated with the occurrence of the local reactions, indurations, swelling, redness, and erythema, and/or occasionally with the systemic adverse events such as fever. Cytokine production was investigated in the early phase following immunization with DPT, Hib, PCV7, JEV, and two HPV vaccines (Cervarix and Gardasil). The quadriceps muscles were dissected from both injected and non-injected sites, and were homogenized. IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-10, Eotaxin, G-CSF, KC, MCP-1, and TNF- $\alpha$  were assayed. Cytokine production was expressed as the ratio of the cytokine concentration in the injected site to that in the non-injected site, and the results of local production are shown in Fig. 6. Changes in TNF- $\alpha$  levels are shown, and ranged between 0.5 and 1.5 fold of those in the injected sites. No significant difference was observed in the cytokine ratios of the injected and non-injected sites for IL-2, IL-4, IL-10, and Eotaxin, which was similar to that of TNF- $\alpha$ . IL-1 $\beta$  levels were 9.8 times higher (injected site 254.26: control 30.57 pg/ml) after 3 h and increased to 47.7 times (injected site 1049.46: control 28.33 pg/ml) 48 h after the inoculation with Cervarix. IL-1 $\beta$  levels were from 2.33 to 2.80 times higher (41.45–84.78 pg/ml) following the inoculation of Gardasil, but were approximately 2–3 times or lower following inoculation with the other vaccines. G-CSF levels were 276 times higher (injected site 96.71: control 0.58 pg/ml) 48 h after the inoculation with Cervarix, and were 23 times higher (injected site 8.78: control 0.59 pg/ml) 24 h after the inoculation with Gardasil. These levels were 13.26 times higher 6 h after DPT and 5.73 times higher 3 h after Hib. IL-6 levels were 139 times higher (injected site 127.26: control 1.09 pg/ml) 48 h after the injection with Cervarix, while the other vaccines increased IL-6 levels by 2–3 times (1.55–4.14 pg/ml). Cervarix induced higher levels of IL-1 $\beta$ , IL-6, and G-CSF, but not significant. It also induced higher MIP-1 levels at 3 h, and these were decreased at 6 h. Higher




**Fig. 4.** Comparison of histological changes after the immunization with three doses of DPT. Injected tissues were obtained 3, 6, and 9 months after the immunization with three doses, and were examined with HE and Lumogallion staining.

levels of these cytokines were induced at 24 and 48 h, and Gardasil induced a similar MIP-1 production pattern (data not shown).

The results of serum cytokine kinetics are shown in Fig. 7. Five mice were assayed and the mean concentrations of five sera are shown. Peaks of IL-1 $\beta$  levels were detected 6 h after the injection of all vaccines, except Hib, which induced peak IL-1 $\beta$  levels 24 h after the injection. Higher IL-1 $\beta$  levels were detected after the injections with PCV7, JEV, and Cervarix. Hib induced a peak in serum G-CSF


levels 3 h after the injection, DPT and Cervarix at 6 h, and PCV7 at 24 h. A significant higher level of IL-6 was observed 3 h after the injection with Cervarix, in comparison with those after the other vaccines, but decreased to the similar level 6 h after the injection with PCV7. All vaccines induced TNF- $\alpha$  and their peak levels were observed within 24 h of the injection with no significant difference.

Cervarix induced extremely high IL-1 $\beta$ , IL-6, and G-CSF levels at the injection site, but, however, systemic serum cytokine levels were similar to the others.



**Fig. 5.** Comparison of histological changes one year after the immunization with three doses of DPT. Injected tissues were examined with HE and Lumogallion staining.





**Fig. 6.** Cytokine production in muscle tissues injected with DPT, Hib, PCV, JEV, Cervarix, and Gardasil. The quadriceps muscles were removed, homogenized, and subjected to BioPlex cytokine panels 3, 6, 24, and 48 h after the injection. Cytokine production was shown as the ratio of the cytokine concentration in the injected site to that in the opposite site. Each bar represents the mean ratio with  $\pm 1.0$  SD of three mice.


### 3.4. Histopathological findings in the early phase following the injection

Cervarix induced higher levels of cytokines at the injection site than those by the other vaccines. Histopathological findings were examined after IM of Cervarix, Gardasil, and JEV. JEV induced no inflammatory responses 1 month after IM, as is shown in Fig. 1, and no pathological changes in the very early phase (data not shown). HE and Lumogallion staining of the series of IM of Cervarix are shown in Fig. 8. Inflammatory nodules were observed 3 h after IM and the predominant infiltrating cells were polymorph nuclear neutrophils (PMNCs) with some eosinophils. Migrating cells engulfing aluminum were observed in the draining inguinal


lymph node 48 h after the injection. These results were similar to those observed after the injection with Gardasil.

### 4. Discussion

The number of reported cases of muscle contracture increased in the 1960s. The histopathological findings of muscle contracture revealed the infiltration of inflammatory cells, muscle cellular necrosis, fibrosis, and scar tissue formation, similar to that in an experimental animal model, and the Investigation Committee on Muscle Contracture suggested that the histopathological changes induced in the muscle tissues of experimental animals by all medicinal preparations through IM should be



**Fig. 7.** Kinetics of serum cytokine production after the injection with DPT, Hib, PCV, JEV, Cervarix, and Gardasil. Serum samples were obtained 3, 6, 24, and 48 h after the injection. Each bar represents the mean ratio with  $\pm 1.0$  SD of three mice.



**Fig. 8.** Histopathological changes in muscular tissues 3, 6, 24 and 48 h after the injection with HPV Cervarix. The middle panels show the HE staining and lower panels show Lumogallion staining. Upper magnified HE staining shows migratory cells in muscle tissues 6 h after immunization. Aluminum positive cells were detected 48 h after the injection with Cervarix. Right upper panels show Lumogallion staining of left inguinal draining lymph node.

examined to assess muscle tissue damage [2]. The objective of the present study was to examine the safety of vaccines through IM. Petousis-Harris et al. [23] recommended vaccine administration techniques to reduce reactogenicity in a specified site of IM, the length of the needle, and injection angle. A significantly higher rate of local reactions was observed following the fifth DTaP vaccination in the arm than in the thigh [6–8]. Kataoka et al. [24] compared the local reactivities of DPTs produced by foreign and Japanese companies that had different local responses in mice. The Japanese DPT caused a milder inflammatory response than that of the DPT produced by foreign vaccine companies. They suggested the possibility of the residual toxicity of DPT components rather than the different concentrations of the aluminum adjuvant. The incidence of local reactogenicity was shown to depend on the vaccine preparation with or without aluminum adjuvant; however, no consistent relationship was observed between the quantity of aluminum and extensive local reactions [25]. Although aluminum has been used as an adjuvant in many kinds of vaccines, no comparative study has examined local reactions after immunizations with different vaccine preparations.

All recommended inactivated vaccines in Japan were tested in the present study. Non-adjuvanted vaccines (influenza, JEV, and Hib vaccines) induced no pathological local reaction, except for small local inflammatory lesions with the infiltration of inflammatory cells without muscle degeneration. Aluminum-adjuvanted vaccines induced inflammatory nodules. DPT, PCV, and Gardasil induced similar changes with central necrosis and the peripheral infiltration of inflammatory cells. Infiltrating cells were similar 1 month after IM with DPT, PCV, and Gardasil, and were positive for F4/80, iNOS, and Arginase I, however, Cervarix induced a different type of macrophage that was positive for F4/80, weakly positive for Arginase I, but negative for iNOS. This suggests a lack of M1 macrophages at the injection site following injection of Cervarix. Diversity and differentiation plasticity are characteristics

of macrophages, which undergo their dynamic changes during different stages of inflammation. In response to the IFNs, chemokines and cytokines signaling through MPL-TLR 4 engagement, macrophages are polarized to M1 phenotype and toward the M2 phenotype by IL-4 and IL-13 [26]. Functional skewing of macrophages occurs under physiological and pathological conditions and the complex mechanisms have been under investigation through the signaling pathways, transcriptional networks, and microenvironments [27].

Inflammatory nodules observed 1 month after IM of Cervarix were identified as macrophagic nodules. The different characteristics of inflammatory nodules may be caused by a combined adjuvant, and may be related to the strong antibody response following the immunization with Cervarix [28]. Aluminum has been used as an adjuvant for a long time because it prolongs the retention of adsorbed antigens at the injection site (depot effect) [29]. Long-term observations following IM or SC of DPT revealed that aluminum was retained until 9–12 months at the injected sites. It is well known that DPT induced inflammatory nodules, which persisted for several months without any pathological signs at the opposite site in *Cynomolgus* monkey [30]. Although a higher volume was used in this study, antigen retention was not required for the potentiation of immunity by aluminum adjuvant, and recent findings on innate immunity have revealed that aluminum adjuvant initiate primary immune-stimulation of the antibody response [31]. Innate immunity consists of two different patterns, PAMPs and DAMPs. PAMPs recognize microbial components or the products of bacteria and viruses, and other endogenous products released from damaged cells (damage or danger signals) stimulate DAMPs, which activate inflammasomes. NALP3 inflammasomes recruit caspase, which converts IL-1 $\beta$  and IL-18 from pro-inflammatory cytokines [32]. The stimulation of inflammasomes is essential for the key mechanism but it is controversial whether NALP3 has an essential role or not for aluminum adjuvant [10,32–34]. These inflammatory cytokines enhanced the expression of the co-stimulatory molecule, which was recognized by CD4 helper cells together

with MHC II [12–14]. Recently, the initiating event is considered to be cellular damage, releasing cellular components, host DNA, and intra-nuclear contents, also known as neutrophil extracellular traps (NETs) [35,36]. They are recognized as DAMPs and stimulate inflammasomes to produce the inflammatory cytokines, IL-1 $\beta$ , IL-18 and TNF- $\alpha$ .

In the present study, histopathological changes and cytokine production were investigated in the very early phase following IM of aluminum-adjuvanted and non-adjuvanted vaccines. PMNCs and eosinophils migrated to the injected site within 3 or 6 h, and macrophages were dominant 1 month after IM. These results were similar to those reported by Lu and HogenEsch [36]. M2 macrophages were dominant 1 month after IM of Cervarix. Cervarix contained a combination of 100  $\mu$ g/ml MPL and 1 g/ml aluminum. MPL induced the migration of neutrophils, monocytes/macrophages, and activated natural killer cells, whereas, aluminum induced the migration of neutrophils and eosinophils, depending on the Th1 and Th2 adjuvants [37]. MF59 was used as an oil emulsion adjuvant for the influenza vaccine, and the immune-stimulating mechanism underlying the new adjuvants MF59 and MPL was extensively investigated in comparison with aluminum [38,39]. However, inflammatory responses stimulated with single component of MPL or aluminum were not evaluated in the present study, and the results represented total effects of AS04. Neutrophils were recruited following IM of Cervarix, which contains a combination of MPL and aluminum, and induced markedly high levels of the inflammatory cytokines, G-CSF, IL-6, KC, and MCP-1, but not TNF- $\alpha$ . G-CSF levels were 276 times higher at 48 h after the injection with Cervarix, and 23 times higher 24 h after the injection of Gardasil. G-CSF levels were 13.26 times higher 6 h after DPT, and 5.73 times higher 3 h after Hib. All tissues, macrophages, endothelial cells, fibroblasts, and mesenchymal cells, are potent producers of G-CSF during infection, which modulates inflammatory responses [40]. G-CSF stimulates myeloid progenitor cells to generate neutrophils and promotes their differentiation into mature neutrophils, and enhances the production of IL-1 $\beta$ , IL-6 and TNF- $\alpha$  from M1 macrophages [26,27,40]. The key functions of neutrophils are bactericidal killing, phagocytosis, and superoxide production, and they also play crucial roles in the initial stage of inflammation [40]. G-CSF was induced at the injected sites, which resulted in the recruitment of neutrophils, followed by NETs. This danger signal stimulates DAMPs to modify acquired immunity, and damage caused by NETs is followed by an inflammatory response by M1 macrophages, which is necessary for limiting the inflammatory areas and cleaning cellular debris. This acute phase inflammation is followed by appearance of M2 macrophages for resolution phase [27,28].

In 2013, the patients with chronic pain were reported following immunization with HPV, and some had unexplained neurological illness. HPV vaccination is temporarily suspended until the causal relationship would be clarified. The present study provides the experimental evidence that inflammatory response was limited at the injected site, not in systemic. Although the nodules persisted for several months, inflammatory responses did not persist over 6–12 months.

In conclusion, all vaccine preparations did not induce the muscle contracture observed through multiple IMs of antibiotics with or without anti-pyretics in an experimental mouse model. Non-adjuvanted vaccines did not induce inflammatory reactions, however, aluminum-adjuvanted vaccines induced inflammatory nodules.

#### Conflict of interest

All authors have no conflict of interest regarding this study.

#### Acknowledgments

This study was supported by Research on Regulatory Science of Pharmaceuticals and Medical Devices Grants, and funding for Research on the Accumulation of Evidence for Effective Vaccine Use and Vaccine Policy, from the Ministry of Health, Labour and Welfare (Chief Investigator Toshiaki Ihara: Department of Pediatrics, National Mie Hospital). We dedicate this study to Dr. Hitoshi Kamiya, Emeritus President of the Japanese Association of Vaccinology, who passed away in 2011. He suggested the necessity of this study. Authors were deeply grateful to Dr. Hideaki Ueki for his help to examine histological experiments.

#### References

- [1] Saitoh A, Okabe N. Current issues with the immunization program in Japan: can we fill the vaccine gap. *Vaccine* 2012;30:4752–6.
- [2] Japan Pediatric Society, Committee on Muscular Contracture. A report of muscular contracture. *J Japan Pediatr Soc* 1983;87:1067–99 [in Japanese].
- [3] Hagen R. Contracture of the quadriceps muscle in children. A report of 12 cases. *Acta Orthop Scand* 1968;39:565–78.
- [4] Theodorou SD. Fibrosis and contracture of the quadriceps muscle in children. *Acta Orthop Belg* 1975;41:285–98.
- [5] Bergeson PS, Singer SA, Kaplan AM. Intramuscular injections in children. *Pediatrics* 1982;70:944–8.
- [6] Jackson LA, Starkovich P, Dunstan M, Yu O, Nelson J, Dunn J, Rees T, Zavitkovsky A, Maus D, Froeschle JE, Decker M. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination. *Pediatrics* 2008;121:e646–52.
- [7] Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. *Vaccine* 2003;22:64–9.
- [8] Rothstein E, Kohl KS, Ball L, Halperin SA, Halsey N, Hammer SJ, Heath PT, Hennig R, Kleppinger C, Labadie J, Varricchio F, Vermeer P, Walop W, Brighton collaboration local reaction working group. Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. *Vaccine* 2004;22:575–85.
- [9] Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kjeland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. *J Immunol* 2009;183:6186–97.
- [10] Kuroda E, Coban C, Ishii KJ. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. *Int Rev Immunol* 2013;32:209–13.
- [11] Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. *J Med Microbiol* 2012;61:927–34.
- [12] Saïd-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. *Biomed J* 2012;35:437–49.
- [13] Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein SA, Offit PA, editors. *Vaccines*. 6th ed. Philadelphia: Elsevier Saunders; 2013. p. 14–32.
- [14] Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. *Science* 2010;327:291–5.
- [15] Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. *Immunity* 2011;33:464–78.
- [16] Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. *Pediatr Res* 2009;65:98R–105R.
- [17] Nakayama T. Vaccine chronicle in Japan. *J Infect Chemother* 2013;19:787–98.
- [18] Gilmour S, Kanda M, Kusumi E, Tanimoto T, Kami M, Shibuya K. HPV vaccination programme in Japan. *Lancet* 2013;382:768.
- [19] Uchiyama A, Takatsu A, Teraki Y. Sensitive detection of trace aluminium in biological tissues by confocal laser scanning microscopy after staining with lumogallion. *Analyst* 1998;123:759–62.
- [20] Redente EF, Higgins DM, Dwyer-Nield LD, Orme IM, Gonzalez-Juarrero M, Malkinson AM. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. *J Leukoc Biol* 2010;88:159–68.
- [21] Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. *J Immunol* 2001;167:6533–44.
- [22] Gobert AP, Cheng Y, Akhtar M, Mersey BD, Blumberg DR, Cross RK, Chaturvedi R, Drachenberg CB, Boucher JL, Hacker A, Casero Jr RA, Wilson KT. Protective role of arginase in a mouse model of colitis. *J Immunol* 2004;173:2109–17.
- [23] Petousis-Harris H, Poole T, Stewart J, Turner N, Goodyear-Smith F, Coster G, Lennon D. An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: a randomized trial. *Vaccine* 2013;31:1157–62.
- [24] Kataoka M, Yamamoto A, Ochiai M, Harashima A, Nagata N, Hasegawa H, Kurata T, Horiuchi Y. Comparison of acellular pertussis-based combination vaccines by

- Japanese control tests for toxicities and laboratory models for local reaction. *Vaccine* 2009;27:1881–8.
- [25] Rennels MB, Deloria MA, Pichichero ME, Englund JA, Anderson EL, Steinhoff MC, Decker MD, Edwards KM. Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. *Vaccine* 2002;20:S44–7.
- [26] Chazaud B. Macrophages: supportive cells for tissue repair and regeneration. *Immunology* 2014;219:172–8.
- [27] Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest* 2012;122:787–95.
- [28] Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Development of an ASO4-adjuvanted HPV vaccine with the adjuvant system approach. *BioDrugs* 2011;25:217–26.
- [29] Gupta RK. Aluminum compounds as vaccine adjuvants. *Adv Drug Deliv Rev* 1998;32:155–72.
- [30] Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey. *Vaccine* 2005;23:1359–67.
- [31] Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiality by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. *Vaccine* 2010;28:3588–94.
- [32] Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. *Nature* 2008;453:1122–6.
- [33] Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht B. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med* 2008;205:869–82.
- [34] Bryant C, Fitzgerald KA. Molecular mechanisms involved in inflammasome activation. *Trend Cell Biol* 2009;19:455–64.
- [35] Munks MW, McKee AS, MacLeod MK, Powell RL, Degen JL, Reisdorph NA, Kappler JW, Marrack P. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. *Blood* 2010;116:5191–9.
- [36] Lu F, HogenEsch H. Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. *Vaccine* 2013;31:3979–86.
- [37] Korsholm KS, Petersen RV, Agger EM, Andersen P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of early inflammatory response at the site of injection. *Immunology* 2010;129:75–86.
- [38] Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. *J Immunol* 2008;180:5402–12.
- [39] Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, Golding H. Use of human MonoMac6 cells for development of *in vitro* assay predictive of adjuvant safety *in vivo*. *Vaccine* 2012;30:4859–65.
- [40] Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! *Growth Factors* 2005;23:33–41.